<SEC-DOCUMENT>0000950142-23-001458.txt : 20230515
<SEC-HEADER>0000950142-23-001458.hdr.sgml : 20230515
<ACCEPTANCE-DATETIME>20230515171439
ACCESSION NUMBER:		0000950142-23-001458
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		19
CONFORMED PERIOD OF REPORT:	20230510
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230515
DATE AS OF CHANGE:		20230515

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			STANDARD BIOTOOLS INC.
		CENTRAL INDEX KEY:			0001162194
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				770513190
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34180
		FILM NUMBER:		23924288

	BUSINESS ADDRESS:	
		STREET 1:		2 TOWER PLACE
		STREET 2:		SUITE 2000
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		6502666000

	MAIL ADDRESS:	
		STREET 1:		2 TOWER PLACE
		STREET 2:		SUITE 2000
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FLUIDIGM CORP
		DATE OF NAME CHANGE:	20011113
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>eh230358911_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-gaap-supplement="http://fasb.org/us-gaap-sup/2022q3" xmlns:srt-supplement="http://fasb.org/srt-sup/2022q3" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:LAB="http://sb.com/20230510">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02B_US%2DGAAP%2D2022 -->
<!-- Field: Set; Name: xdx; ID: xdx_033_LAB_sb.com_20230510 -->
<!-- Field: Set; Name: xdx; ID: xdx_04D_20230510_20230510 -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DEntityCentralIndexKey_0001162194 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2023-05-10to2023-05-10" name="dei:EntityCentralIndexKey">0001162194</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-05-10to2023-05-10" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="lab-20230510.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2023-05-10to2023-05-10">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001162194</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-10</xbrli:startDate>
        <xbrli:endDate>2023-05-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>UNITED STATES<br />
SECURITIES AND EXCHANGE COMMISSION<br />
WASHINGTON, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: center"><b>FORM <span id="xdx_90C_edei--DocumentType_c20230510__20230510_zwmycijLgDl4"><ix:nonNumeric contextRef="From2023-05-10to2023-05-10" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: center"><b>CURRENT REPORT<br />
PURSUANT TO SECTION 13 OR 15(D) OF<br />
THE SECURITIES EXCHANGE ACT OF 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Date of report (Date of earliest event reported):
<span id="xdx_90F_edei--DocumentPeriodEndDate_c20230510__20230510_zqxDqjcto82"><ix:nonNumeric contextRef="From2023-05-10to2023-05-10" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">May 10, 2023</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_900_edei--EntityRegistrantName_c20230510__20230510_z6c5nrREf7Q9"><ix:nonNumeric contextRef="From2023-05-10to2023-05-10" name="dei:EntityRegistrantName">Standard BioTools Inc.</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact name of registrant as specified in its charter)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid; width: 33%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_900_edei--EntityIncorporationStateCountryCode_c20230510__20230510_zL895qoZbXqc"><ix:nonNumeric contextRef="From2023-05-10to2023-05-10" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="border-bottom: Black 1pt solid; width: 34%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90D_edei--EntityFileNumber_c20230510__20230510_zTQqpsDcQzpk"><ix:nonNumeric contextRef="From2023-05-10to2023-05-10" name="dei:EntityFileNumber">001-34180</ix:nonNumeric></span></b></span></td>
    <td style="border-bottom: Black 1pt solid; width: 33%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90F_edei--EntityTaxIdentificationNumber_c20230510__20230510_zsm6aOUa85fb"><ix:nonNumeric contextRef="From2023-05-10to2023-05-10" name="dei:EntityTaxIdentificationNumber">77-0513190</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction <br />
of incorporation)</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission <br />
File Number)</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S. Employer <br />
Identification No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid; width: 100%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0; text-align: center"><b><span id="xdx_90A_edei--EntityAddressAddressLine1_c20230510__20230510_zXxf0O9XwUP6"><ix:nonNumeric contextRef="From2023-05-10to2023-05-10" name="dei:EntityAddressAddressLine1">2 Tower Place</ix:nonNumeric></span>, <span id="xdx_909_edei--EntityAddressAddressLine2_c20230510__20230510_z9Of7apTSpIk"><ix:nonNumeric contextRef="From2023-05-10to2023-05-10" name="dei:EntityAddressAddressLine2">Suite 2000</ix:nonNumeric></span></b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0; text-align: center"><b><span id="xdx_905_edei--EntityAddressCityOrTown_c20230510__20230510_ziaWv64CoPZ1"><ix:nonNumeric contextRef="From2023-05-10to2023-05-10" name="dei:EntityAddressCityOrTown">South San Francisco</ix:nonNumeric></span>, <span id="xdx_900_edei--EntityAddressStateOrProvince_c20230510__20230510_zVGDG5Nb20Ei"><ix:nonNumeric contextRef="From2023-05-10to2023-05-10" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">California</ix:nonNumeric></span> <span id="xdx_90D_edei--EntityAddressPostalZipCode_c20230510__20230510_zK2Ni3CgPFCj"><ix:nonNumeric contextRef="From2023-05-10to2023-05-10" name="dei:EntityAddressPostalZipCode">94080</ix:nonNumeric></span></b></p></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of principal executive offices) (Zip Code)</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(<span id="xdx_90A_edei--CityAreaCode_c20230510__20230510_z7LUAWfInWw9"><ix:nonNumeric contextRef="From2023-05-10to2023-05-10" name="dei:CityAreaCode">650</ix:nonNumeric></span>) <span id="xdx_902_edei--LocalPhoneNumber_c20230510__20230510_zZ9h5fscTYV8"><ix:nonNumeric contextRef="From2023-05-10to2023-05-10" name="dei:LocalPhoneNumber">266-6000</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant&#8217;s Telephone Number, Including Area Code)</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Former Name or Address, if Changed Since Last Report)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 2%; text-align: justify">&#160;</td>
    <td style="width: 4%; text-align: justify"><span id="xdx_902_edei--WrittenCommunications_c20230510__20230510_zrxKNGYE7Uw1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="From2023-05-10to2023-05-10" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--SolicitingMaterial_c20230510__20230510_zLxGus3rI1Gf"><ix:nonNumeric contextRef="From2023-05-10to2023-05-10" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span id="xdx_903_edei--PreCommencementTenderOffer_c20230510__20230510_zsWQQV3yhKA9" style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2023-05-10to2023-05-10" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act&#160;&#160;&#160;(17&#160;CFR&#160;240.14d-2(b))</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--PreCommencementIssuerTenderOffer_c20230510__20230510_z3W5jGttzS0e"><ix:nonNumeric contextRef="From2023-05-10to2023-05-10" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act&#160;&#160;(17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; width: 47%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of each class</b></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 33%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Name of each exchange on which registered</b></p></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_90F_edei--Security12bTitle_c20230510__20230510_zTNj87trD6ac"><ix:nonNumeric contextRef="From2023-05-10to2023-05-10" name="dei:Security12bTitle">Common Stock, $0.001 par value</ix:nonNumeric></span></p>
</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--TradingSymbol_c20230510__20230510_zZwafB97aKQ2"><ix:nonNumeric contextRef="From2023-05-10to2023-05-10" name="dei:TradingSymbol">LAB</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_edei--SecurityExchangeName_c20230510__20230510_zpf36cGfWzQg"><ix:nonNumeric contextRef="From2023-05-10to2023-05-10" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq Global Select Market</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(&#167;240.12b-2 of this chapter).</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-indent: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif">Emerging
growth company </span><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_edei--EntityEmergingGrowthCompany_c20230510__20230510_z3ha1TKW3ZRh"><ix:nonNumeric contextRef="From2023-05-10to2023-05-10" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Wingdings 2">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Wingdings 2"></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Wingdings 2">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Wingdings 2"></span></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 2px solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->






<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 3.35pt; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0%"></td><td style="width: 1in"><b>Item 5.02</b></td><td><b>Departure of Directors or Certain Officers; Election of Directors; Appointment
of Certain Officers; Compensatory Arrangements of Certain Officers.</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Appointment of Chief Financial Officer </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 15, 2023, Standard BioTools Inc. (the &#8220;Company&#8221;)
announced the appointment of Jeffrey G. Black, age 54, as Chief Financial Officer of the Company, effective as of May 15, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Mr. Black served as Senior Vice President and Chief Financial Officer of
Apollo Endosurgery Inc., a publicly listed medical technology company focused on endoscopic therapies <span style="background-color: white">for
gastrointestinal conditions and interventional treatment of obesity</span>, from August 2021 until April 2023, when Apollo was acquired
by Boston Scientific. Prior to joining Apollo, he served as Executive Vice President and Chief Financial Officer of Alphatec Holdings,
Inc., a publicly listed medical technology company focused on the surgical treatment of spinal disorders, from March 2017 to April 2021.
Prior to joining Alphatec, Mr. Black was Senior Vice President and Chief Financial Officer of Applied Proteomics, Inc., a proteomics-based
diagnostics company, Senior Vice President and Chief Financial Officer of AltheaDx, Inc., a pharmacogenetics diagnostics company, and
Senior Vice President and Chief Financial Officer of Verenium Corporation, an industrial biotechnology company. Mr. Black began his career
at Ernst &amp; Young LLP. Mr. Black is a member of the board of directors of Cellana, Inc., where he serves as chair of the audit committee.
Mr. Black received his B.S. in Business from the University of Arizona.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">The Company entered into an offer letter with
Mr. Black (&#8220;Offer Letter&#8221;) pursuant to which he will be <span style="background-color: white">an&#160;at-will&#160;employee
of the Company. Pursuant to the Offer Letter, he will receive an annual base salary of $415,000 and be eligible to receive an annual bonus
with a target level of 55% of his annual base salary, prorated based on his date of hire. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; background-color: white">As a material inducement for Mr. Black
to commence employment with the Company, he will receive an award of stock options to purchase 400,000 shares of the Company&#8217;s common
stock (&#8220;Option Award&#8221;). The Option Award will have a 10-year term and an exercise price per share equal to the closing price
of the Company&#8217;s common stock as quoted on the Nasdaq Global Select Market on&#160;May 15, 2023. Subject to his continued employment
with the Company through the applicable vesting dates, 25% of the shares subject to the Option Award will vest on the first anniversary
of the vesting commencement date, and the remaining 75% of the shares subject to the Option Award will vest in roughly equal monthly installments
thereafter. In addition, as a material inducement for&#160;Mr. Black&#160;to commence employment with the Company, he will receive an
award of restricted stock units valued at&#160;$400,000&#160;(&#8220;RSU Award&#8221;) based on the closing price of the Company&#8217;s
common stock on&#160;May 15, 2023. Subject to his continued employment with the Company, 25% of the shares underlying the RSU Award will
vest on the first anniversary of the vesting commencement date and the remaining 75% of the shares underlying the RSU Award will vest
in roughly equal installments every three months thereafter until fully vested in&#160;May 2027. <span style="background-color: white">The
Option Award and RSU Award will be subject to the terms of the Company&#8217;s 2022 Inducement Equity Incentive Plan and the applicable
award agreements thereunder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; background-color: white">The Company also entered into its 2020
Change of Control and Severance Plan Participation Agreement (&#8220;Severance Plan Participation Agreement&#8221;) with Mr. Black, with
terms substantially as set forth under &#8220;Change of Control and Severance Plan&#8221; in the Company&#8217;s 2021 proxy statement
filed April 14, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; background-color: white">The foregoing descriptions of the Offer
Letter and the Severance Plan Participation Agreement are qualified in their entirety by reference to the full text of the Offer Letter,
a copy of which is filed as Exhibit&#160;10.1 hereto, and the terms of which are incorporated by reference herein, and the Severance Plan
Participation Agreement, a copy of which is filed as Exhibit 10.2 hereto, and the terms of which are incorporated by reference herein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; background-color: white">The Company expects to enter into its form
of indemnification agreement for directors and executive officers with Mr.&#160;Black, which requires the Company to indemnify its directors
and executive officers for certain expenses, including attorneys&#8217; fees, judgments, penalties, fines and settlement amounts incurred
by a director or an executive officer in any action or proceeding arising out of their services as one of the Company&#8217;s directors
or executive officers or as a director, officer or other fiduciary of any other company or enterprise to which the person provides services
at the Company&#8217;s request.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="background-color: white">There are no family relationships
between Mr.&#160;Black and any director or executive officer of the Company, and the Company has not entered into any transactions with
Mr.&#160;Black that are reportable pursuant to Item 404(a) of Regulation&#160;S-K.&#160;Except as described above, there are no arrangements
or understandings between Mr.&#160;Black and any other persons pursuant to which he was selected to be the Company&#8217;s Chief Financial
Officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="background-color: white">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0"></p>


<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 2px solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="background-color: white">On May 15, 2023, the Company issued
a press release regarding the appointment of Mr.&#160;Black. The full text of the press release is attached as Exhibit&#160;99.1 hereto.
The information in Exhibit 99.1 hereto is being furnished and shall not be deemed to be &#8220;filed&#8221; for purposes of Section&#160;18
of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liability of that section,
nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange
Act, except as expressly set forth by specific reference in such a filing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Departure of Chief Financial Officer</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; background-color: white">In connection with the appointment of Mr.
Black as Chief Financial Officer, Vikram Jog&#8217;s last day as the Company&#8217;s Chief Financial Officer was May 14, 2023. From May
15, 2023 until June 9, 2023 it is expected that Mr. Jog will remain an employee of the Company in the role of Special Advisor, reporting
to the Company&#8217;s Chief Executive Officer. A letter agreement dated May 10, 2023 was entered into between the Company and Mr. Jog
(&#8220;Letter Agreement&#8221;) that provides for the following severance benefits: (a) as required by the Company&#8217;s 2020 Change
of Control and Severance Plan, cash severance benefits equal to 75% of Mr. Jog&#8217;s annual base salary, payment by the Company of continued
health coverage under COBRA for nine months, and reasonable outplacement services; and (b) accelerated vesting of equity. The foregoing
description of the Letter Agreement is qualified in its entirety by reference to the full text of the Letter Agreement, a copy of which
is filed as Exhibit&#160;10.3 hereto, and the terms of which are incorporated by reference herein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 3.35pt; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 0%"></td>
    <td style="width: 1in"><b>Item 9.01</b></td>
    <td><b>Financial Statements and Exhibits.</b></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; background-color: white">(d) Exhibits.</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: Black 1pt solid; vertical-align: top; width: 0.9in"><span style="font-size: 10pt"><b>Exhibit Number</b></span></td>
    <td style="padding-bottom: 1pt; width: 0.1in">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; vertical-align: bottom"><span style="font-size: 10pt"><b>Title</b></span></td>
    </tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.1</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="eh230358911_ex1001.htm">Offer letter by and between Standard BioTools Inc. and Jeffery G. Black executed May 10, 2023</a></span></td>
    </tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.2 </span></td>
    <td>&#160;</td>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><a href="eh230358911_ex1002.htm">Standard BioTools Inc. 2020 Change of Control and Severance Plan Participation Agreement by and between Jeffery G. Black and Standard BioTools Inc. dated May 10, 2023</a></p></td>
    </tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.3</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="eh230358911_ex1003.htm">Letter agreement by and between Standard BioTools Inc. and Vikram Jog dated May 10, 2023</a></span></td>
    </tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">99.1</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="eh230358911_ex9901.htm">Press release of Standard BioTools Inc. dated May 15, 2023</a></span></td>
    </tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt; background-color: white">Cover Page Interactive Date File (embedded within the Inline XBRL document)</span></td>
    </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>


<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 2px solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0pt 0pt">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td colspan="2" style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>STANDARD BIOTOOLS
                                            INC.</b></p></td>
    <td>&#160;</td></tr>
  <tr>
    <td style="width: 50%">&#160;</td>
    <td style="width: 5%">&#160;</td>
    <td style="width: 35%">&#160;</td>
    <td style="width: 10%">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: May 15,
    2023</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="vertical-align: bottom">
    <p style="border-bottom: black 0.75pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0 0 1pt">/s/ Hanjoon Alex Kim</p></td>
    <td>&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Hanjoon Alex Kim</p></td>
    <td>&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Chief Operating Officer</p></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 283.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 2px solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjV0KwjAQhE/QOyx5Fm2CivbRoiJWkSLia7RbCbbZsol/R/KWxhZxWViWmW9GiJ5Y0sJUyHCc5RnssW4q7RFyLJHRnjE40tU6gXBzvBjnWVvfvj8wpcBgYEZ9OT4FobXejcMiASkHajJQCmKZDKew24joq6dkS1Og9UZXoG0BO6aGDXrNry5hr59kqX61VQdkZ8iGuH7cyW9QsVSwpbt+EF8dZFkqol47kVgy3Zpvzc15qmFeYR26XIf+N/oAHVJJUg== -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>eh230358911_ex1001.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>EXHIBIT
10.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 15%"><IMG SRC="logo.jpg" ALT=""></TD>
  <TD STYLE="text-align: left; width: 85%; vertical-align: middle"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt; color: Black"><I>Join
                                            an innovative team driven by a bold vision &ndash;</I></FONT></P><P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 5pt 0pt 0pt; color: #44536A"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt; color: Black"><I>unleashing
                                            tools to accelerate breakthroughs in human health</I></FONT></P></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">May
9, 2023</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Jeff
Black</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">4132
Garfield Street</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Carlsbad,
CA 92008</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Dear
Jeff:</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">We
are pleased to offer you the position of <U>Senior Vice President and Chief Financial Officer</U> with Standard BioTools Inc, reporting
to Michael Egholm, Chief Executive Officer and President. You will perform work duties from your home in Carlsbad, California. Additionally,
you will be expected to travel to other locations to attend meetings and/or conduct business reviews in the ordinary course of your job
responsibilities.</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">It
is an extraordinary time for Standard BioTools. Our technology is empowering customers to improve life by providing tools to accelerate
breakthroughs in human health. We invite you to join a leading provider of indispensable life sciences tools that is accelerating global
research on multiple frontiers.</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">At
Standard BioTools, we are building a positive culture where our people can do the best work of their careers, informed, and influenced
by our core values:</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>Customer
                                            Commitment.</B> We are committed to developing quality solutions to meet our customers&rsquo;
                                            unmet needs.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD><FONT STYLE="font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>Integrity.
                                            </B>We uphold the highest standards professionally, personally, and intellectually.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD><FONT STYLE="font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>Respect.
                                            </B>We show respect for each other, value every voice, and embrace diversity, equity, and
                                            inclusion.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD><FONT STYLE="font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>Continuous
                                            Improvement.</B> We foster a culture of continuous improvement that drives us to do better
                                            every day.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">We
hope you are as excited about this opportunity as we are delighted to have you on our team.</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The
following is a summary of the terms and conditions of this offer, which will apply to your employment with Standard BioTools:</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><U>Start
Date:</U> May 15, 2023</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B><U>Compensation:</U></B></FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">You
will receive an initial salary of $17,291.66 per pay period. We are on a semi-monthly pay schedule with two pay periods per calendar
month which generally fall on the 15th and the last day of the month. This equates to a base compensation of $415,000 on an annual basis,
less deductions as required by law, which will be paid in accordance with the Company&rsquo;s normal payroll procedures. This is an exempt
position.</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><U>Bonus
Target:</U></FONT></P>

<P STYLE="text-align: justify; font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">You
will be eligible to participate in the Company&rsquo;s Employee Bonus Plan. The bonus will be subject to achievement of performance objectives
with the actual bonus amount to be determined by the Company in its discretion. To earn a bonus, you must remain employed with the Company
through the date bonuses are paid, as well as having commenced your employment on or prior to September 30 of the corresponding bonus
plan&rsquo;s performance year. For purposes of calculating any bonus payout you earn, your target bonus amount will initially be 55%
of your annual base salary, and the company will waive any prorated plan requirements related to your hire date for the 2023 performance
year.</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 15%"><IMG SRC="logo.jpg" ALT=""></TD>
  <TD STYLE="text-align: left; width: 85%; vertical-align: middle"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt; color: Black"><I>Join
                                            an innovative team driven by a bold vision &ndash;</I></FONT></P><P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 5pt 0pt 0pt; color: #44536A"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt; color: Black"><I>unleashing
                                            tools to accelerate breakthroughs in human health</I></FONT></P></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: bold 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><U>Equity
Award:</U></FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">You
will receive a grant of stock options to purchase 400,000 shares of Standard BioTools Corporation&rsquo;s Common Stock based on the stock
price at the close of market May 15, 2023. Additionally, you will receive a new hire grant of Restricted Stock Units valued at $400,000
USD based upon the value of LAB stock at the close of market May 15, 2023. Your grant will be subject to the terms of our equity incentive
plan and policies governing grants of equity incentive awards.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: bold 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><U>Benefits:</U></FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">You
are eligible to receive the Company&rsquo;s standard benefits package which currently includes medical, dental, vision, life, and disability
insurance benefits. Benefits will be effective on your date of hire. Additional benefits, as the Company may make generally available
to its employees from time to time, will be made available to you. You will be entitled to participate in the Flexible Vacation Plan
as well as paid holidays the Company gives to its employees generally, in accordance with company policies.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><U>Workers&rsquo;
Compensation Insurance:</U></FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The
Company provides a comprehensive workers&rsquo; compensation insurance program at no cost to employees. This program covers any injury
or illness sustained in the course of employment that requires medical, surgical or hospital treatment. Insurance carrier: Preferred
Employers Group - PO BOX 85838, San Diego, CA 92186, phone number (866) 472-9602.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><U>Confidentiality
and Company Policies:</U></FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">It
is important to protect our confidential information and proprietary material. Therefore, as a condition of employment you will be required
to sign the Company&rsquo;s standard At-Will Employment, Confidential Information, Invention Assignment, and Arbitration Agreement.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B><U>Background
and reference checks:</U></B> This offer is contingent upon successfully passing your background and reference checks.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><U>Employment
Authorization:</U></FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">For
purposes of federal immigration law, you will be required to provide to the Company documentary evidence of your identity and eligibility
for employment in the United States. Such documentation must be provided to us within 3 business days of your date of hire, or our employment
relationship may be terminated.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: bold 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><U>Other:</U></FONT></P>

<P STYLE="text-align: justify; font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">This
offer of employment and its related terms will expire on <B><U>May 12, 2023</U></B>.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">This
letter shall be interpreted under California law. You should be aware that your employment with the Company is for no specified period
and constitutes &ldquo;at will&rdquo; employment. As a result, you are free to resign at any time, for any reason or for no reason. Similarly,
the Company is free to conclude its employment relationship with you at any time, with or without cause. In addition, the Company may
change your compensation, duties, assignments, responsibilities, location of your position, or any other terms and conditions of employment
at any time to adjust to the changing needs of our dynamic Company.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">In
the event of any dispute or claim relating to or arising out of our employment relationship, you and the Company agree that all such
disputes shall be fully and finally resolved by binding arbitration conducted by the Judicial Arbitration &amp; Mediation Services (&ldquo;JAMS&rdquo;)
in Santa Clara County California. The current JAMS employment arbitration rules &amp; procedures can be found at <U>http://www.jamsadr.com/rules-employment-arbitration/</U>.
The JAMS employment arbitration rules &amp; procedures may, however, be amended by JAMS. You acknowledge that you are waiving your right
to a jury trial.</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 15%"><IMG SRC="logo.jpg" ALT=""></TD>
  <TD STYLE="text-align: left; width: 85%; vertical-align: middle"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt; color: Black"><I>Join
                                            an innovative team driven by a bold vision &ndash;</I></FONT></P><P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 5pt 0pt 0pt; color: #44536A"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt; color: Black"><I>unleashing
                                            tools to accelerate breakthroughs in human health</I></FONT></P></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="text-align: justify; font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">To
indicate your acceptance of the Company's offer, please sign and date this letter in the space provided below and return it via Adobe
Sign to our Talent Acquisition Team.</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">This
letter, along with the agreement relating to proprietary rights between you and the Company, set forth the terms of your employment with
the Company and supersede any prior representations or agreements, whether written or oral. This letter may not be modified or amended
except by a written agreement, signed by the Company and by you.</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">We
look forward to you joining and being part of Standard BioTools! I am certain we can build a great company together.</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Sincerely,</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><IMG SRC="image_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Betsy
Jensen</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Chief
Human Resources Officer</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Standard BioTools Inc.</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">ACCEPTED
AND AGREED TO:</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%"><IMG SRC="image_002.jpg" ALT=""></TD>
  <TD STYLE="text-align: left; width: 50%; vertical-align: middle"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">10 May 2023</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>Jeffrey Black</B></FONT></TD>
  <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>Date</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><B></B></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>eh230358911_ex1002.htm
<DESCRIPTION>EXHIBIT 10.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>EXHIBIT 10.2</B></FONT></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 12pt; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>Executive
Leadership Team Members</B></FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 12pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>Appendix
A</B></FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 12pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>Standard
BioTools Inc. 2020 Change of Control and Severance Plan Participation Agreement</B></FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 12pt; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Standard
BioTools Inc. (the &ldquo;<B><I>Company</I></B>&rdquo;) is pleased to inform you that you have been selected to participate in the Company&rsquo;s
2020 Change of Control and Severance Plan (the &ldquo;<B><I>Plan</I></B>&rdquo;) as a Participant.</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 12pt; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">A
copy of the Plan was delivered to you with this Participation Agreement. Your participation in the Plan is subject to all of the terms
and conditions of the Plan. The capitalized terms used but not defined herein will have the meanings ascribed to them in the Plan.</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 12pt; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">In
order to actually become a participant in the Plan, you must complete and sign this Participation Agreement.</FONT></P>

<P STYLE="font: bold 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 12pt; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Definition
of &ldquo;Good Reason&rdquo;</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 12pt; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&ldquo;<B><I>Good
Reason</I></B>&rdquo; means the occurrence of one or more of the following events effected without your prior consent, provided you terminate
your employment with the Company within one (1) year following the initial existence of the &ldquo;Good Reason&rdquo; condition (discussed
below): (i) the assignment to you of any duties or the reduction of your then-current duties, either of which results in a material diminution
in your then-current position or responsibilities with the Company including, without limitation, any negative change in reporting hierarchy
involving you or the person to whom you directly report; (ii) a material reduction by the Company in your then- current base salary;
(iii) a material change in the geographic location at which you must perform services (for purposes of this Participation Agreement,
your relocation to a facility or a location less than 25 miles from your then-present location shall not be considered a material change
in geographic location); or (iv) any material breach by the Company of any material provision of this Participation Agreement. You will
not resign for Good Reason without first providing the Company with written notice of the acts or omissions constituting the grounds
for &ldquo;Good Reason&rdquo; within 90 days of the initial existence of the grounds for &ldquo;Good Reason&rdquo; and a reasonable cure
period of not less than 30 days following the date of such notice.</FONT></P>

<P STYLE="font: bold 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 12pt; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Non-COC
Involuntary Termination</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 12pt; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">If,
outside of the Change of Control Period, you incur a Non-COC Involuntary Termination, then subject to the terms and conditions of the
Plan, you will receive:</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Cash Severance Benefits</B>. An aggregate amount equal to 75% of your annual base salary in effect as of the date of your Non-COC Involuntary
Termination paid in equal installments over a period of nine (9) months following your termination date.</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Continued Medical Benefits</B>. Payment by the Company of continued health coverage under COBRA for a period of nine (9) months following
your termination of employment. Notwithstanding the foregoing, if you are not employed in the United States, the benefit under this paragraph
will be a regional equivalent to COBRA determined by the Administrator in its sole discretion.</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 60%">&nbsp;</TD><TD STYLE="width: 40%; text-align: right"><P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><B>STANDARD BIOTOOLS INC. 2020 CHANGE OF CONTROL AND</B></FONT></P><P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><B>SEVERANCE PLAN AND SUMMARY PLAN DESCRIPTION &ndash;</B></FONT></P><P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><B>FORM OF ELT PARTICIPATION AGREEMENT</B></FONT></P></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Outplacement Services</B>. Outplacement services as described in Section 4.3 of the Plan.</FONT></P>



<P STYLE="font: bold 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 12pt; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">COC
Involuntary Termination</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 12pt; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">If,
during the Change of Control Period, you incur a COC Involuntary Termination, then subject to the terms and conditions of the Plan, you
will receive:</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Cash Severance Benefits</B><FONT STYLE="font-weight: normal">.</FONT></FONT></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 59.95pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">a.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">A
                                            lump-sum payment equal to 150% of the sum of (x) your annual base salary (as in effect immediately
                                            prior to the Change of Control or your COC Involuntary Termination, whichever is greater),
                                            plus (y) the greater of (A) your annual target bonus (as in effect immediately prior to the
                                            Change of Control or your COC Involuntary Termination, whichever is greater) or (B) the average
                                            of the annual bonuses actually paid to you for the three (3) fiscal years preceding the year
                                            in which your COC Involuntary Termination occurs. For the avoidance of doubt, if you incurred
                                            a termination prior to a Change of Control that qualifies as a COC Involuntary Termination,
                                            then you will be entitled to a lump-sum payment of the amount calculated under the preceding
                                            sentence, less amounts already paid as cash Severance Benefits for a Non-COC Involuntary
                                            Termination.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify; padding-right: 5.7pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 60pt"></TD><TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">b.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">A
                                            lump sum amount equal to (i) your annual target bonus (as in effect immediately prior to
                                            the Change of Control or your COC Involuntary Termination, whichever is greater), multiplied
                                            by (ii) a fraction, the numerator of which is the number of days worked by you during the
                                            year in which the COC Involuntary Termination occurs and the denominator of which is 365.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Continued Medical Benefits</B>. Payment by the Company of continued health coverage under COBRA for a period of 18 months following your
termination of employment. Notwithstanding the foregoing, if you are not employed in the United States, the benefit under this paragraph
will be a regional equivalent to COBRA determined by the Administrator in its sole discretion.</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Equity Award Vesting Acceleration</B>. 100% of your then-outstanding and unvested Equity Awards will become vested in full. If, however,
an outstanding Equity Award is to vest and/or the amount of the award to vest is to be determined based on the achievement of performance
criteria, then, unless expressly otherwise provided in the applicable Equity Award agreement, the Equity Award will vest as to 100% of
the &ldquo;Baseline Number of Restricted Stock Units&rdquo; or &ldquo;Baseline Number of Performance Units&rdquo; (as defined in the
Company&rsquo;s grant agreements) or the equivalent measure of the number of units or shares that vest at 100% of target levels of achievement
under the relevant Equity Award. Except otherwise provided in the applicable Equity Award agreement, shares owed upon such vesting (and
exercise if applicable) of Equity Awards will issued to you as promptly as practicable and no more than 30 days after they become issuable
(whether through the vesting acceleration alone or upon an exercise of options following such vesting acceleration). Notwithstanding
the foregoing, to the extent that the payment or settlement of an Equity Award is subject to Section 409A, the Equity Award will be paid
or settled in a manner that will meet the</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-family: Arial, Helvetica, Sans-Serif; width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 60%">&nbsp;</TD><TD STYLE="width: 40%; text-align: right"><P STYLE="text-align: left; font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0 0 0 1pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><B>STANDARD BIOTOOLS INC. 2020 CHANGE OF CONTROL AND</B></FONT></P><P STYLE="text-align: left; font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0 0 0 1pt; text-indent: -0.05pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><B>SEVERANCE PLAN AND SUMMARY PLAN DESCRIPTION &ndash; FORM OF ELT PARTICIPATION AGREEMENT</B></FONT></P></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 12pt; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">requirements
of Section 409A such that the payment or settlement will not be subject to the additional tax or interest applicable under Section 409A.</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Outplacement
Services</B>. Outplacement services as described in Section 5.4 of the Plan.</FONT></P>



<P STYLE="font: bold 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 12pt; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Additional
Benefits</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 12pt; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">In
addition to the foregoing benefits, in addition to the Plan benefits described above, if, during the Change of Control Period, you incur
a COC Involuntary Termination, then subject to the terms and conditions of the Plan, the Company will reimburse your reasonable attorneys&rsquo;
fees incurred in connection with the review of the Release and any related separation agreements and documents, up to $5,000.</FONT></P>

<P STYLE="font: bold 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 12pt; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">General
Provisions</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 12pt; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">For
clarity, any severance payments provided for herein that are based on annual base salary (and any reduction to base salary constituting
&ldquo;Good Reason&rdquo;) shall be calculated without giving effect to any temporary reduction in base salary imposed by the Company
or agreed to by you in connection with any global pandemic or comparable global or U.S. emergency that threatens the Company&rsquo;s
economic position.</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 12pt; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">In
order to receive any Severance Benefits for which you otherwise become eligible under the Plan, you must sign and deliver to the Company
the Release, which must have become effective and irrevocable within the requisite period set forth in the Plan.</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 5.95pt; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><I>[Remainder
of This Page Intentionally Left Blank]</I></FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 5.95pt; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 5.95pt; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 5.95pt; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 5.95pt; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-family: Arial, Helvetica, Sans-Serif; width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 60%">&nbsp;</TD><TD STYLE="width: 40%; text-align: right"><P STYLE="text-align: left; font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0 0 0 1pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><B>STANDARD BIOTOOLS INC. 2020 CHANGE OF CONTROL AND</B></FONT></P><P STYLE="text-align: left; font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0 0 0 1pt; text-indent: -0.05pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><B>SEVERANCE PLAN AND SUMMARY PLAN DESCRIPTION &ndash; FORM OF ELT PARTICIPATION AGREEMENT</B></FONT></P></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><I></I>By
your signature below, you and the Company agree that your participation in the Plan is governed by this Participation Agreement and the
provisions of the Plan. Your signature below confirms that: (1) you have received a copy of the 2020 Change of Control and Severance
Plan and Summary Plan Description; (2) you have carefully read this Participation Agreement and the 2020 Change of Control and Severance
Plan and Summary Plan Description; (3) decisions and determinations by the Administrator under the Plan will be final and binding on
you and your successors; and (4) participation in the Plan and this Participation Agreement replaces in its entirety any severance and/or
change of control provisions set forth in any offer letter, employment agreement and/or Equity Award agreement, including, but not limited
to, the Prior Plan.</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Arial, Helvetica, Sans-Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 40%"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>STANDARD BIOTOOLS </B></FONT><B>INC.</B></TD>
  <TD STYLE="width: 20%">&nbsp;</TD>
  <TD STYLE="width: 40%"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>PARTICIPANT</B></font></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-bottom: Black 1pt solid">/s/ Betsy Jensen</TD>
  <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt">/s/ <FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Jeffrey G. Black</font></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Signature</font></TD>
  <TD>&nbsp;</TD>
  <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Signature</font></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Betsy
    Jensen</font></TD>
  <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Jeffrey
    G. Black</font></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Name</font></TD>
  <TD>&nbsp;</TD>
  <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Name</font></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">CHRO</font></TD>
  <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">10
    May 2023</font></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Title</font></TD>
  <TD>&nbsp;</TD>
  <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Date</font></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0.5pt 0 0; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Attachment:
Standard BioTools Inc. 2020 Change of Control and Severance Plan and Summary Plan Description</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><I>[Signature
Page to the Participation Agreement]</I></FONT></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-family: Arial, Helvetica, Sans-Serif; width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>eh230358911_ex1003.htm
<DESCRIPTION>EXHIBIT 10.3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>EXHIBIT 10.3</B></FONT></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 3.95pt 119.3pt 0 124.3pt; text-align: center">STANDARD BIOTOOLS INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 0 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 4.5pt; margin-bottom: 0pt">May 10, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt">Vikram Jog</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt">10645 Eloise Circle</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt">Los Altos Hills, CA 94024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt">Dear Vikram:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0.05pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">This letter
agreement (this &ldquo;<B><I>Agreement</I></B>&rdquo;) sets forth the terms and conditions relating to certain benefits that you may become
eligible to receive in the event of your termination of employment from Standard BioTools Inc. (the &ldquo;<B><I>Company</I></B>&rdquo;).</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">For valuation
consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, the Company and
you hereby agree as follows:</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0.5pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">1.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Term</U></B>. The term of this Agreement will commence as of May 10, 2023 (such date, the &ldquo;<B><I>Effective Date</I></B>&rdquo;)
and will remain in effect until the Termination Date. For purposes of this Agreement, the &ldquo;<B><I>Termination Date</I></B>&rdquo;
will mean the earliest of (i) June 9, 2023 (the &ldquo;<B><I>Retention Date</I></B>&rdquo;), and (ii) the date that your employment with
the Company is terminated. The period of time from the Effective Date through the Termination Date is herein referred to as the &ldquo;<B><I>Term</I></B>.&rdquo;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0.55pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">2.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Termination of Employment; Resignation from Positions</U></B>. The parties agree that your employment and any and all titles,
positions and appointments that you hold with the Company or any of its subsidiaries and affiliates (the &ldquo;<B><I>Company Group</I></B>&rdquo;),
whether as an officer, director, employee, consultant, trustee, committee member, agent or otherwise, will terminate on the Termination
Date, and you will be deemed to have resigned from all such titles, positions and appointments as of the Termination Date. Effective as
of the Termination Date, you will have no authority to act on behalf of any member of the Company Group in any manner, or otherwise act
in an executive or other decision-making capacity with respect to any member of the Company Group. You agree to promptly execute such
documents as the Company Group, in its sole discretion, will deem necessary to effect such resignations.</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0.5pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0.05pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">3.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Entitlements</U></B>. Subject to your agreement and compliance with the terms and conditions set forth in this Agreement
(including, without limitation, your employment not being terminated by the Company for Cause or due to your voluntary resignation prior
to the Retention Date), and, subject to <U>Section 4</U> below, the Company will provide you with the following benefits:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0.5pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.75in">a.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Cash Severance Benefits</U>. An aggregate amount equal to 75% of your annual base salary in effect as of the Termination Date,
paid in substantially equal installments over a period of nine (9) months following the Termination Date.</P>

<P STYLE="text-indent: 0.75in; font: 10pt Times New Roman, Times, Serif; margin-top: 0.5pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.75in">b.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Continued Medical Benefits</U>. Payment by the Company of continued health coverage for you and your eligible dependents under
COBRA for a period of nine (9) months</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: justify; text-indent: 59.75pt">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 3.95pt; margin-bottom: 0pt">following the Termination Date; <U>provided</U> that you
validly elect and are eligible to continue coverage under COBRA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0.5pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.75in">c.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Equity Award Vesting Acceleration</U>. 100% of your then-outstanding and unvested stock options, stock appreciation rights,
restricted stock, restricted stock units, performance shares, performance stock units and any other Company equity compensation award
(collectively, the &ldquo;<B><I>Equity Awards</I></B>&rdquo;) will become vested in full. If, however, an outstanding Equity Award is
to vest and/or the amount of the award to vest is to be determined based on the achievement of performance criteria, then, unless expressly
otherwise provided in the applicable Equity Award agreement, the Equity Award will vest as to 100% of the &ldquo;Baseline Number of Restricted
Stock Units&rdquo; or &ldquo;Baseline Number of Performance Units&rdquo; (as defined in the Company&rsquo;s grant agreements) or the equivalent
measure of the number of units or shares that vest at 100% of target levels of achievement under the relevant Equity Award. Except otherwise
provided in the applicable Equity Award agreement, shares owed upon such vesting (and exercise if applicable) of Equity Awards will be
issued to you as promptly as practicable and no more than 30 days after they become issuable (whether through the vesting acceleration
alone or upon an exercise of options following such vesting acceleration). Notwithstanding the foregoing, to the extent that the payment
or settlement of an Equity Award is subject to Section 409A, the Equity Award will be paid or settled in a manner that will meet the requirements
of Section 409A such that the payment or settlement will not be subject to the additional tax or interest applicable under Section 409A.</P>

<P STYLE="text-indent: 0.75in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.75in">d.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
</FONT><U>Outplacement Services</U>. Reasonable outplacement services in accordance with any applicable Company policy in effect as of
the Termination Date (or if no such policy is in effect, as determined by the Company, in its sole discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0.5pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">4.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Termination Benefits Requirement</U></B>. Payments described in <U>Section 3</U> above are conditioned on (i) your execution
and nonrevocation of the Release of Claims set forth on <U>Appendix A</U> hereto (the &ldquo;<U>Release</U>&rdquo;) no later than the
60<SUP>th</SUP> day following the Termination Date (the &ldquo;<B><I>Release Deadline</I></B>&rdquo;), and (ii) your continued compliance
with the restrictive covenants set forth under any confidentiality, proprietary information and inventions agreement and such other appropriate
agreement between you and the Company. If the Release does not become effective and irrevocable by the Release Deadline Date, you will
forfeit any right to the benefits set forth in <U>Section 3</U>, and in no event will such benefits be paid or provided until the Release
becomes effective and irrevocable.</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0.55pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">5.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Timing of Benefits</U></B>. Provided that the Release becomes effective and irrevocable by the Release Deadline and subject
to <U>Section 7(c)</U> below, the payments and benefits set forth in <U>Section 3</U> will be paid (or in the case of payments and benefits
scheduled to be paid in installments, will commence) no later than the first Company payroll date that is at least fourteen (14) days
following the date in which the Release of Claims becomes effective and enforceable (such payment date, the &ldquo;<B><I>Severance Start
Date</I></B>&rdquo;), and any payments or benefits otherwise payable to you during the period immediately following the Termination Date
through the Severance Start Date will be paid in a lump sum to you on the Severance Start Date, with any remaining payments to be made
as provided in this Agreement.</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0.5pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Definitions</U></B><FONT STYLE="font-weight: normal">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: justify; text-indent: 35.95pt">&nbsp;</P>




<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 3.95pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.75in">a.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B><I>Cause</I></B>&rdquo; for purposes of this Agreement will mean (i) your conviction of, or plea of guilty or nolo contendere
to, any crime involving dishonesty or moral turpitude or any felony; or (ii) your (a) engagement in material dishonesty, willful misconduct,
or gross negligence-in each case in connection with your position at the Company; (b) breach of any confidentiality, invention assignment,
non-disclosure, or non-solicitation agreement entered into between you and the Company; (c) material violation of a written Company policy
or procedure that has been provided to you, which violation causes substantial injury to the Company; or (d) willful refusal to perform
your assigned duties to the Company, following written notice of such refusal by the Company and a period of fifteen (15) days to cure
the same and your failure to cure during such time period. No act or omission will be considered &ldquo;willful&rdquo; if such act or
omission was done, or not done, in the reasonable, good-faith belief that such act or omission was in the best interests of the Company
or upon the advice of counsel to the Company.</P>

<P STYLE="text-indent: 0.75in; font: 10pt Times New Roman, Times, Serif; margin-top: 0.55pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.75in">b.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B><I>COBRA</I></B>&rdquo;
will mean the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended.</P>

<P STYLE="text-indent: 0.75in; font: 10pt Times New Roman, Times, Serif; margin-top: 0.5pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.75in">c.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B><I>Section
409A</I></B>&rdquo; will mean Section 409A of the Internal Revenue Code and the regulations and guidance promulgated thereunder.</P>

<P STYLE="text-indent: 0.75in; font: 10pt Times New Roman, Times, Serif; margin-top: 0.5pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.75in">d.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B><I>Section
409A Limit</I></B>&rdquo; will mean two (2) times the lesser of: (i) the your annualized compensation based upon the annual rate of pay
paid to you during the taxable year preceding the taxable year of your termination of employment as determined under, and with such adjustments
as are set forth in, Treasury Regulation 1.409A-1(b)(9)(iii)(A)(1) and any Internal Revenue Service guidance issued with respect thereto;
or (ii) the maximum amount that may be taken into account under a qualified plan pursuant to Section 401(a)(17) of the Code for the year
in which the your employment is terminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0.55pt; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>General Provisions</U></B><FONT STYLE="font-weight: normal">.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0.5pt; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.75in">a.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Calculation of Base Salary Payments</U>. For clarity, any payments provided for herein that are based on annual base salary
will be calculated without giving effect to any temporary reduction in base salary imposed by the Company or agreed to by you in connection
with any global pandemic or comparable global or U.S. emergency that threatens the Company&rsquo;s economic position.</P>

<P STYLE="text-indent: 0.75in; font: 10pt Times New Roman, Times, Serif; margin-top: 0.5pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0.05pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.75in">b.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>CIC Plan; Exclusive Benefits</U>. For the avoidance of doubt, the terms of this Agreement shall not supersede the Company&rsquo;s
2020 Change of Control and Severance Plan and your related participation agreement (collectively, the &ldquo;<B><I>CIC Plan</I></B>&rdquo;),
and the CIC Plan shall remain in effect pursuant to the terms and conditions thereunder; <U>provided</U>, <U>however</U>, that the provisions
of this Agreement shall not result in the duplication of any payments or benefits that may be payable to you under the CIC Plan. Except
as otherwise provided in this Section 7(b) with respect to the CIC Plan, (A) the payments and benefits provided under this Agreement will
be the exclusive benefit for you related to your termination of employment and/or retirement and will supersede and replace any severance
and/or change in control benefits set forth in any offer letter, employment agreement and/or severance agreement, and (B) if you were
otherwise eligible to participate in any other Company severance plan (whether or not subject to ERISA), this Agreement will supersede
and replace eligibility in such other plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0.05pt; margin-bottom: 0; text-align: justify; text-indent: 59.75pt">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.75in"> c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
 <U>Taxes; Section 409A Compliance</U>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: justify; text-indent: 1in">i.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company will withhold from any payments or benefits under this Agreement all applicable U.S. federal, state, local and non-U.S.
taxes required to be withheld and any other required payroll deductions.</P>

<P STYLE="text-indent: 1in; font: 10pt Times New Roman, Times, Serif; margin-top: 0.5pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: justify; text-indent: 1in">ii.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Notwithstanding anything to the contrary in this Agreement, no payments or benefits to be paid or provided to you, if any, under
this Agreement that, when considered together with any other severance payments or separation benefits, are considered deferred compensation
under Section 409A (together, the &ldquo;<B><I>Deferred Payments</I></B>&rdquo;) will be paid or provided until you experience a &ldquo;separation
from service&rdquo; within the meaning of Section 409A. Similarly, no severance payable to you, if any, under this Agreement that otherwise
would be exempt from Section 409A pursuant to Treasury Regulation Section 1.409A 1(b)(9) will be payable until you experience a &ldquo;separation
from service&rdquo; within the meaning of Section 409A.</P>

<P STYLE="text-indent: 1in; font: 10pt Times New Roman, Times, Serif; margin-top: 0.55pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: justify; text-indent: 1in">iii.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>It is intended that none of the severance payments or benefits under this Agreement will constitute Deferred Payments but rather
will be exempt from Section 409A as a payment that would fall within the &ldquo;short-term deferral period&rdquo; as described below or
resulting from an involuntary separation from service as described in below. In no event will you have discretion to determine the taxable
year of payment of any Deferred Payment.</P>

<P STYLE="text-indent: 1in; font: 10pt Times New Roman, Times, Serif; margin-top: 0.5pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: justify; text-indent: 1in">iv.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Notwithstanding anything to the contrary in this Agreement, if you are deemed a &ldquo;specified employee&rdquo; within the meaning
of Section 409A at the time of your separation from service (other than due to death), then the Deferred Payments, if any, that are payable
within the first six (6) months following the your separation from service, will become payable on the date six (6) months and one (1)
day following the date of your separation from service. All subsequent Deferred Payments, if any, will be payable in accordance with the
payment schedule applicable to each payment or benefit. Notwithstanding anything herein to the contrary, in the event of your death following
your separation from service, but before the six-month anniversary of the separation from service, then any payments delayed in accordance
with this paragraph will be payable in a lump sum as soon as administratively practicable after the date of your death and all other Deferred
Payments will be payable in accordance with the payment schedule applicable to each payment or benefit. Each payment and benefit payable
under this Agreement is intended to constitute a separate payment under Section 1.409A- 2(b)(2) of the Treasury Regulations.</P>

<P STYLE="text-indent: 1in; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: justify; text-indent: 1in">v.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>For purposes of this Section 7, (A) any amount paid under this Agreement that satisfies the requirements of the &ldquo;short-term
deferral&rdquo; rule set forth in Section 1.409A-1(b)(4) of the Treasury Regulations will not constitute Deferred Payments; and (B) any
amount paid under this Agreement that qualifies as a payment made as a result of an involuntary separation from service pursuant to Section
1.409A-1(b)(9)(iii) of the Treasury Regulations that does not exceed the Section 409A Limit will not constitute Deferred Payments.</P>

<P STYLE="text-indent: 1in; font: 10pt Times New Roman, Times, Serif; margin-top: 0.5pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: justify; text-indent: 1in">vi.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The foregoing provisions are intended to comply with or be exempt from the requirements of Section 409A so that none of the payments
and benefits to be provided under this Agreement will be subject to the additional tax imposed under Section 409A, and any ambiguities
herein will be interpreted to so comply or be exempt. Notwithstanding anything to the contrary in this Agreement, the Company reserves
the right to amend this Agreement as it</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: justify; text-indent: 59.6pt">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 3.95pt; margin-bottom: 0pt; text-align: justify">deems necessary or advisable, in
its sole discretion and without your consent, to comply with Section 409A or to avoid income recognition under Section 409A prior to the
actual payment of benefits under this Agreement or imposition of any additional tax. In no event will the Company reimburse you for any
taxes that may be imposed on you as result of Section 409A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0.5pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.75in">d.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT><U>Successors and Assigns</U>. The provisions of this Agreement will be binding upon your heirs, executors, administrators, legal
representatives and assigns. The Company&rsquo;s rights under this Agreement may, without your consent, be assigned by the Company, in
its sole and unfettered discretion, to any person, firm, corporation or other business entity which at any time, whether by purchase,
merger or otherwise, directly or indirectly, acquires all or substantially all of the assets or business of the Company. You may not assign
any of your rights and/or obligations under this Agreement without the prior written consent of the Company, and any such attempted assignment
without the prior written consent of the Company will be void. A failure of any of the parties to insist on strict compliance with any
provision of this Agreement will not be deemed a waiver of such provision or any other provision hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.75in">e.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Governing Law</U>. This Agreement will be governed by and construed in accordance with the laws of the State of California without
regard to any conflicts of laws that would result in the application of the laws of any other jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0.5pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.75in">f.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
</FONT><U>Counterparts</U>. This Agreement may be executed in one or more counterparts, all of which taken together will be deemed to
constitute one and the same original. Each party hereto confirms that any facsimile copy of such party&rsquo;s executed counterpart of
the Agreement (or its signature page thereof) shall be deemed to be an executed original thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0.5pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.75in">g.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT><U>Entire Agreement; Severability</U>. This Agreement constitutes the entire agreement between the Company and you concerning the
subject matter hereof and may not be modified or amended, nor may any rights under it be waived, except in a writing signed and agreed
to by you and the Company. If any provision of this Agreement is held invalid or unenforceable, its invalidity or unenforceability will
not affect any other provision of the Agreement, and the Agreement will be construed and enforced as if such provision had not been included.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><I>[Remainder of This Page Intentionally
Left Blank]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Please indicate
your understanding and acceptance of this Agreement by executing your signature below. By your signature below, you and the Company agree
that your entitlement to any severance payments or benefits upon your termination of employment is governed by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">Very truly yours,</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P></TD>
    <TD STYLE="vertical-align: bottom"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>STANDARD
                                       BIOTOOLS INC.</B></FONT></P></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"></TD>
    <TD STYLE="vertical-align: bottom"></TD>
    <TD STYLE="vertical-align: bottom"><P STYLE="border-bottom: black 0.75pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0 0 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/
    Betsy Jensen</FONT></P></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">By:
                                       Betsy Jensen</FONT></P></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:
                                       CHRO</FONT></P></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 283.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 0 0">I hereby accept the terms of this Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 0 0">And agree to
abide by the provisions hereof:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="border-bottom: Black 1pt solid; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Vikram Jog</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: Vikram Jog</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 283.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25pt 0 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">[<I>Signature Page to Jog Letter Agreement</I>]</P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 3pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Appendix
A</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0.1pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 4.5pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Release
of Claims</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0.05pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further
to the letter agreement dated May 10, 2023, from Standard BioTools (the &ldquo;<B><I>Company</I></B>&rdquo;) to me (the &ldquo;<B><I>Severance
Agreement</I></B>&rdquo;) referencing this Release of Claims (this &ldquo;<B><I>Release Agreement</I></B>&rdquo;), I, the undersigned
Vikram Jog, hereby agree as follows:</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0.35pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>CONSIDERATION</U>. Pursuant to the Severance Agreement, this Release Agreement is given in exchange for payments and benefits described
in Section 3 of the Severance Agreement. <B>I understand that these are additional benefits for which I am not eligible unless I elect
to sign this Release Agreement, and that if I do not sign this Release Agreement on or before the deadline for such signature as specified
herein, I will lose my eligibility for such severance benefits.</B> I further understand that my participation in all benefits and incidents
of employment, including, but not limited to, vesting in equity grants, and the accrual of bonuses, commissions, vacation, and paid time
off, ceased as of the Termination Date (defined below). I agree that this Release Agreement is not given in return for the payment of
any wages undisputedly due or owing. I also understand and agree that I will not be entitled to such benefits if I am not employed through
the date specified by the Company for termination of my employment (the &ldquo;<B><I>Termination Date</I></B>&rdquo;) or if I commence
employment elsewhere within the Company or with an affiliated or related company or receive an offer of employment with a successor to
the Company or any of its affiliated or related companies prior to receiving such consideration. I acknowledge and represent that, other
than the consideration set forth in this Section 1, the Company has paid or provided all salary, wages, bonuses, accrued vacation/paid
time off, premiums, leaves, housing allowances, relocation costs, interest, severance, outplacement costs, fees, reimbursable expenses,
commissions, stock, stock options, vesting, and any and all other benefits and compensation due to me.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0.05pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>TIMING OF PAYMENT OF SEVERANCE</U>. I understand that the payments and benefits described in Section 3 of the Severance Agreement
will be payable in accordance with the Company&rsquo;s standard payroll practices in equal installments commencing no later than the
first payroll date that is at least fourteen (14) days after this Release Agreement becomes effective and enforceable (as described in
Section 5 below). The initial severance payment will include a catch- up payment for the full amount that would have been paid for any
payroll periods that occurred from the Termination Date through such initial payment date had the Release Agreement been effective on
the Termination Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0.05pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0.05pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

<U>PROPRIETARY INFORMATION OBLIGATIONS.</U> I acknowledge and reaffirm my continuing obligations under my Employment, Confidential Information
and Invention Assignment Agreement, a copy of which will be provided at a future date as <U>Schedule A</U>. My signature below constitutes
my certification under penalty of perjury that I have returned all documents and other items provided to me by the Company (with the
exception of a copy of the employee handbook and personnel documents specifically relating to my employment),</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0.05pt; margin-bottom: 0pt; text-align: justify; text-indent: 35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">RELEASE AGREEMENT</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 3pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">developed
or obtained by me in connection with my employment with the Company, or otherwise belonging to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0.25pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>RELEASED CLAIMS</U>. Except as outlined under Protected Rights (defined below), in exchange for the above considerations, I, on behalf
of my heirs, spouse and assigns, hereby completely release and forever discharge the Company, its past, present and future parent companies,
subsidiaries, affiliates, partners, members, managers, trustees (in their official and individual capacities), employee benefit plans
and their fiduciaries (in their official and individual capacities), related entities, and each of their past, present and future agents,
officers, directors, shareholders, employees, attorneys, insurers, predecessors, successors and assigns (collectively, the &ldquo;<B><I>Released
Parties</I></B>&rdquo;) from any and all claims, of any and every kind, nature and character, known or unknown, foreseen or unforeseen,
based on any act or omission occurring prior to the date of my signing this Release Agreement, to the fullest extent allowed by law,
including but not limited to any claims arising out of my offer of employment, my employment or termination of my employment with the
Company, my right to purchase, or actual purchase of shares of stock of the Company, including, without limitation, any claims for fraud,
misrepresentation, breach of fiduciary duty, breach of duty under applicable state corporate law, and securities fraud under any state
or federal law, and any and all claims for wrongful discharge of employment, termination in violation of public policy, discrimination,
harassment, retaliation, breach of contract (both express and implied), breach of covenant of good faith and fair dealing (both express
and implied), promissory estoppel, negligent or intentional infliction of emotional distress, fraud, negligent or intentional misrepresentation,
negligent or intentional interference with contract or prospective economic advantage, unfair business practices, defamation, libel,
slander, negligence, personal injury, assault, battery, invasion of privacy, false imprisonment, conversion, and disability benefits.
The matters released include, but are not limited to, any claims under federal, state or local laws, including claims arising under the
Age Discrimination in Employment Act of 1967 (&ldquo;<B><I>ADEA</I></B>&rdquo; as amended by the Older Workers&rsquo; Benefit Protection
Act (&ldquo;<B><I>OWBPA</I></B>&rdquo;), the National Labor Relations Act, Title VII of the Civil Rights Act of 1964, the Civil Rights
Act of 1991, the Rehabilitation Act of 1973, the Americans with Disabilities Act of 1990, the Equal Pay Act, the Fair Labor Standards
Act, the Securities Act of 1933, the Securities Exchange Act of 1934, the Fair Credit Reporting Act, the Employee Retirement Income Security
Act of 1974, the Worker Adjustment and Retraining Notification Act, the Family and Medical Leave Act, the Sarbanes- Oxley Act of 2002,
the Immigration Reform and Control Act, the California Family Rights Act, the California Labor Code, the California Workers&rsquo; Compensation
Act and the California Fair Employment and Housing Act, each as amended and any common law tort, contract or statutory claims, and any
claims for attorneys&rsquo; fees and costs. I understand and agree that with the exception of excluded Protected Rights claims, this
Release Agreement extinguishes all claims, whether known or unknown, foreseen or unforeseen.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0.25pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
acknowledge and represent that I have no lawsuits, claims or actions pending in my name, or on behalf of myself or any other person or
entity, against the Released Parties. I agree that I will not voluntarily provide assistance, information or advice, directly or indirectly
(including through agents or attorneys), to any person or entity in connection with any actual or potential claim or cause of action
of any kind against the Released Parties and I will not induce or encourage any person or entity to do so, unless compelled or authorized
to do so by law or as related directly to the ADEA waiver in this Release Agreement. Notwithstanding the foregoing, I understand and
agree that I retain the right to file a charge with the Equal Employment Opportunity Commission</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">RELEASE AGREEMENT</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(the
&ldquo;<B><I>EEOC</I></B>&rdquo;) and equivalent state and local agencies, and to cooperate with investigations by any such agencies.
I agree that this Release Agreement may be pleaded as a full defense to any action, suit, arbitration or other proceeding covered by
the terms hereof which is or may be initiated, prosecuted or maintained by me, my descendants, dependents, heirs, executors, administrators
or permitted assigns.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">I
acknowledge and represent that I have not suffered any discrimination or harassment by the Company or any of the Released Parties on
account of race, gender, age, national origin, religion, marital or registered domestic partner status, sexual orientation, disability,
veteran status, medical condition or any other characteristic protected by law. I acknowledge and represent that I have not been denied
any leave, benefits or rights to which I have been entitled to under any federal or state law, and that I have not suffered any job-related
wrongs or injuries for which I might be entitled to compensation or relief.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
provisions of this Release Agreement shall be binding upon my heirs, executors, administrators, legal representatives and assigns. A
failure of any of the Released Parties to insist on strict compliance with any provision of this Release Agreement shall not be deemed
a waiver of such provision or any other provision hereof. If any provision of this Release Agreement is determined to be so broad as
to be unenforceable, such provision shall be interpreted to be only so broad as is enforceable, and in the event that any provision is
determined to be entirely unenforceable, such provision shall be deemed severable, such that all other provisions of this Release Agreement
shall remain valid and binding upon me and the Released Parties. For the avoidance of doubt, each of the Released Parties shall be a
third-party beneficiary to this Release Agreement and shall be entitled to enforce this Release Agreement in accordance with its terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>TIMING TO CONSIDER, SIGN, AND REVOKE RELEASE</U>. I acknowledge that I am waiving and releasing any rights I may have under the Age
Discrimination in Employment Act of 1967 (&ldquo;<B><I>ADEA</I></B>&rdquo;) and that this release is knowing and voluntary. I further
acknowledge that this waiver and release does not apply to any rights or claims that may arise under the ADEA after the Release Effective
Date of this Release Agreement (as defined below) and that the consideration provided for this waiver and release is in addition to anything
of value to which I was already entitled. I have been informed by the Company that I should consult with an attorney before signing this
Release Agreement, if I wish, at my own expense, and have been given at least five (5) business days prior to signing this Release Agreement
to do so. I acknowledge that I have been advised that I have forty-five (45) days from the date of receipt of this Release Agreement
to consider all the provisions of this Release Agreement and to the extent that I sign this Release Agreement prior to the expiration
of such period and return it to the Company&rsquo;s Human Resources Department I hereby knowingly and voluntarily waive the remaining
portion of such forty-five <FONT STYLE="font-weight: normal">(45) day period, </FONT><B><U>provided that I must deliver the signed Release
Agreement no earlier than the end of my work day on my Termination Date</U></B><FONT STYLE="font-weight: normal">.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Once this signed
Release Agreement is returned to Betsy Jensen, Chief Human Resources Officer, <FONT STYLE="color: Blue"><U>betsy.jensen@standardbio.com</U></FONT>,
I can revoke it by notifying Betsy Jensen, Chief Human Resources Officer in writing via hand delivery, email or fax no later than
seven (7) calendar days following my execution of this Release Agreement. The Company and I agree that any later agreed-upon changes
to this Agreement, whether material or immaterial, do not restart the running</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">RELEASE AGREEMENT</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">of
the 45-day period. This Release Agreement shall not become effective or enforceable until such revocation period has expired.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>DIFFERENCE IN FACTS</U>. I expressly waive any rights or benefits under Section 1542 of the California Civil Code, or any equivalent
statute. California Civil Code Section 1542 provides as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.35pt 0 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 78.15pt 0 84pt; text-align: justify">&ldquo;A GENERAL RELEASE DOES
NOT EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING
THE RELEASE, AND THAT IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR RELEASED PARTY.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.45pt 0 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">I
fully understand that, if any fact with respect to any matter covered by this Release Agreement is found hereafter to be other than or
different from the facts now believed by me to be true, I expressly accept and assume that this Release Agreement shall be and remain
effective, notwithstanding such difference in the facts.</FONT></P>

<P STYLE="text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>ENFORCEMENT</U>. I understand and agree that if I breach any term in this Release Agreement, the Company may stop any payments or
benefits otherwise owing hereunder and may seek additional relief or remedy as permitted by law. I also understand and agree that if
any suit, affirmative defense, or counterclaim is brought to enforce the provisions of this Release Agreement, with the exception of
Protected Rights claims, the prevailing party shall be entitled to its costs, expenses, and attorneys&rsquo; fees as well as any and
all other remedies specifically authorized under the law.</FONT></P>

<P STYLE="text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>NO ADMISSION OF LIABILITY</U>. I understand and agree that this Release Agreement shall not be deemed or construed at any time or
for any purposes as an admission of any liability or wrongdoing by either myself or the Company.</FONT></P>

<P STYLE="text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>AGREEMENT NOT TO SUE; NON-DISPARAGEMENT</U>. I agree not to pursue any action nor seek damages or any other remedies for any released
claims. I agree to execute any and all documents necessary to request dismissal or withdrawal, or to opt-out, of such claims with prejudice.
I agree not to disparage, defame, or otherwise make, endorse, publicize or circulate to any person or entity, any statement or remark
that can reasonably be construed as disparaging to the Company, or make any statement concerning any of them which in any way could harm
or interfere with the Company&rsquo;s business or personal interests or reputation. Notwithstanding the foregoing, I understand that
I may respond accurately and fully to any question, inquiry or request for information when required by legal process. I understand this
provision does not in any way limit my right to file a charge with the EEOC or equivalent state or local agencies, or to cooperate with
investigations by any federal, state or local agencies. I also understand that nothing in this agreement prevents me from discussing
or disclosing information about unlawful acts in the workplace, such as harassment or discrimination or any other conduct that I have
reason to believe is unlawful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">RELEASE AGREEMENT</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>CONFIDENTIALITY</U>. I further acknowledge that during my employment, I may have obtained confidential, proprietary and trade secret
information, including information relating to the Company&rsquo;s products, plans, designs and other valuable confidential information.
Except as provided under the Protected Rights section below, I agree not to use or disclose any such confidential information unless
required by subpoena or court order and that I will first give the Company written notice of such subpoena or court order with reasonable
advance notice to permit the Company to oppose such subpoena or court order if it chooses to do so. I will further agree that, except
as provided under the Protected Rights section below or unless required to do so by law, I will not disclose voluntarily or allow anyone
else to disclose either the existence, reason for or contents of this Release Agreement without the prior written consent of the Company.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Notwithstanding
this provision, I am authorized to disclose this Release Agreement to my spouse, attorneys and tax advisors on a &ldquo;need to know&rdquo;
basis, on the condition that they agree to hold the terms of the Release Agreement, including the severance payment(s), in strictest
confidence. I am further authorized to make appropriate disclosures in response to a subpoena, provided that I notify the Company in
writing of such legal obligations to disclose at least five (5) business days in advance of disclosure. No such notice, however, is required
if I make disclosure of confidential information of this Release Agreement in the process of exercising my right or ability to file a
charge or claim or communicate or cooperate with any federal, state or local agency, including providing documents or other information
as set forth under the Protected Rights section below.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>PROTECTED RIGHTS</U>. I understand this Release Agreement does not release any claims that cannot be released as a matter of law,
including any right I may have to unemployment compensation benefits. I further understand no provision in this Release Agreement, including
Sections 4, 9, and 11, is intended to or shall limit, prevent, impede or interfere with my non- waivable right, without prior notice
to the Company, to provide information to the government, participate in investigations, testify in proceedings regarding the Company&rsquo;s
past or future conduct, or engage in any activities protected under whistleblower statutes, or to receive and fully retain a monetary
award from a government- administered whistleblower award program for providing information directly to a government agency or as otherwise
permitted by law.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">I
also understand that pursuant to the Defend Trade Secrets Act of 2016, I shall not be held criminally, or civilly, liable under any federal
or state trade secret law for the disclosure of a trade secret that is made in confidence either directly or indirectly to a federal,
state, or local government official, or an attorney, for the sole purpose of reporting, or investigating, a violation of law. Moreover,
I understand employees may disclose trade secrets in a complaint, or other document, filed in a lawsuit, or other proceeding, if such
filing is made under seal. Finally, I understand an employee who files a lawsuit alleging retaliation by a company for reporting a suspected
violation of the law may disclose the trade secret to the attorney of the employee and use the trade secret in the court proceeding,
if the employee files any document containing the trade secret under seal and does not disclose the trade secret, except pursuant to
court order.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Further,
I understand that claims challenging the validity of this Release Agreement under the ADEA as amended by the OWBPA are not
released.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">RELEASE AGREEMENT</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>TAXES</U>. I understand and agree to the withholding by the Company of taxes from amounts payable under the Severance Agreement as
required by law, and that I will be solely responsible for the payment of all income and other taxes due or that may become due (with
the sole exception of FICA contributions) because of the consideration received by me as described in the Severance Agreement, including
but not limited to those imposed by federal, state, county and municipal jurisdictions. I further agree to indemnify and hold the Company
harmless against any taxes, interest, penalties, or other charges assessed in connection with the consideration described herein.</FONT></P>

<P STYLE="text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
understand and agree with the Company that: (i) It is intended that this Release Agreement, the Severance Agreement and any severance
benefits contemplated comply with, or be exempt from, Code Section 409A and the final regulations and official guidance thereunder (&ldquo;<B><I>Section
409A</I></B>&rdquo;) and any ambiguities herein will be interpreted to so comply and/or be exempt from Section 409A, (ii) each payment
and benefit to be paid or provided is intended to constitute a series of separate payments for purposes of Section 1.409A-2(b)(2) of
the Treasury Regulations and (iii) all payments hereunder will be made no later than [ ].<SUP>1</SUP> Notwithstanding any provision of
this Release Agreement to the contrary, to the extent that the Company, in its sole discretion, determines that any payments or benefits
hereunder may not be either compliant with or exempt from Section 409A of the Code and related Department of Treasury guidance, I and
the Company will work together to adopt such amendments to this Release Agreement, the Severance Agreement or take such other actions
that the Company determines are necessary or appropriate to (A) exempt the compensation and benefits payable under the Severance Agreement
from Section 409A of the Code and/or preserve the intended tax treatment of such compensation and benefits, or (B) comply with the requirements
of Section 409A of the Code and related Department of Treasury guidance; provided, however, that this paragraph shall not create any
obligation on the part of the Company to adopt any such amendment or take any other action, nor shall the Company have any liability
for failing to do so.</FONT></P>

<P STYLE="text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>ENTIRE AGREEMENT</U>. This Release Agreement, pursuant to the Severance Agreement, constitutes the entire agreement between me and
the Company with respect to any matters referred to in this Release Agreement. This Release Agreement together with the Severance Agreement
supersedes any and all of the other agreements between myself and the Company, except for my Employment, Confidential Information and
Invention Assignment Agreement<B>, </B>attached hereto, which remains in full force and effect, unless a provision therein is expressly
contradicted in this Release Agreement. No other consideration, agreements, representations, oral statements, understandings or course
of conduct which are not expressly set forth in this Release Agreement should be implied or are binding. I am not relying upon any other
agreement, representation, statement, omission, understanding, or course of conduct which is not expressly set forth in this Release
Agreement.</FONT></P>

<P STYLE="text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

<U>GOVERNING LAW, FORUM AND SEVERABILITY</U>. The terms and conditions
of this Release Agreement will be interpreted and construed in accordance with the laws of California and federal law. I further agree
that if a claim for enforcement of this Release Agreement and/or the Severance Agreement is brought that I consent to the jurisdiction
of San</FONT></P>

<P STYLE="margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">RELEASE AGREEMENT</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Mateo
County, California or Northern District of California federal court. I also agree that if any provision of this Release Agreement is
deemed invalid, the remaining provisions will still be given full force and effect.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>KNOWING AND VOLUNTARY RELEASE</U>. I have read this Release Agreement and understand all of its terms. Prior to execution of this
Release Agreement, I have apprised myself of sufficient relevant information in order that I might intelligently exercise my own judgment.
I further acknowledge and agree that this Release Agreement is executed voluntarily and with full knowledge of its legal significance.
I confirm I have been given forty-five (45) days to consider whether or not to enter into this Release Agreement (although I may elect
not to use the full 45-day period at my option)</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>[Remainder
of this page intentionally left blank.]</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">RELEASE AGREEMENT</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">ACCEPTANCE OF RELEASE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">I HAVE CAREFULLY READ AND FULLY UNDERSTAND
AND VOLUNTARILY AGREE TO ALL THE TERMS OF THE RELEASE AGREEMENT IN EXCHANGE FOR THE ADDITIONAL SEVERANCE TO WHICH I WOULD OTHERWISE NOT
BE ENTITLED.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Deliver your signature below to the Company on or after
your Termination Date. <U>Do not execute this Release Agreement before your actual Termination Date.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: __________________</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom"></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Vikram Jog</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD>
    <TD STYLE="vertical-align: bottom"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>STANDARD
                                       BIOTOOLS INC.</B></FONT></P></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: __________________</FONT></TD>
    <TD STYLE="vertical-align: bottom"></TD>
    <TD STYLE="vertical-align: bottom"><P STYLE="border-bottom: black 0.75pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0 0 1pt"></P></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
                                       Betsy Jensen</FONT></P></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
                                       CHRO</FONT></P></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 283.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">RELEASE AGREEMENT</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 3.95pt 116.3pt 0 124.3pt; text-align: center">Schedule A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.15pt 0 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 116.35pt 0 124.3pt; text-align: center">Employment, Confidential Information
and Invention Assignment Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.3pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 116.45pt 0 124.3pt; text-align: center"><I>(to be attached at future date)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 116.45pt 0 124.3pt; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 116.45pt 0 124.3pt; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 116.45pt 0 124.3pt; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 116.45pt 0 124.3pt; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 116.45pt 0 124.3pt; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 116.45pt 0 124.3pt; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 116.45pt 0 124.3pt; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 116.45pt 0 124.3pt; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 116.45pt 0 124.3pt; text-align: center"><I></I></P>

<!-- Field: Page; Sequence: 15; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 116.45pt 0 124.3pt; text-align: center"><I>&nbsp;</I></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>eh230358911_ex9901.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT 99.1</B></FONT></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: bold 12pt Times New Roman, Times, Serif; margin: 0 0 0in; text-align: center">Standard BioTools Appoints Jeffrey Black
as Chief Financial Officer and</P>

<P STYLE="font: bold 12pt Times New Roman, Times, Serif; margin: 0 0 0in; text-align: center">Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: center"><I>Industry veteran Jeffrey Black brings
30 years of financial and operating leadership experience</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: center"><I>Vikram Jog to become Special Advisor
for transition period</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">SOUTH SAN FRANCISCO, Calif., May 15, 2023 &mdash; Standard BioTools Inc.&nbsp;(Nasdaq:
LAB), driven by a bold purpose &ndash;&nbsp;<I>Unleashing tools to accelerate breakthroughs in human health</I> &ndash;announced the appointment
of Jeffrey Black as Senior Vice President and Chief Financial Officer effective today. Black will lead Standard BioTools&rsquo; finance,
accounting and investor relations functions, reporting to Michael Egholm, PhD., President and Chief Executive Officer. Vikram Jog will
remain at the company for a period as Special Advisor to the CEO to ensure an effective transition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&ldquo;We are excited to welcome Jeff to the Standard BioTools executive
leadership team. Jeff has a proven track record of driving performance for high-growth public companies and his extensive operating experience
and financial stewardship will be critical as Standard BioTools enters its next phase of growth,&rdquo; said Egholm. &ldquo;I also want
to extend my gratitude to Vikram, who has been a steady hand and clear thinker as we navigated the strategic transformation throughout
our first year as Standard BioTools.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Mr. Black was most recently Chief Financial Officer at Apollo Endosurgery,
Inc. until Apollo&rsquo;s acquisition by Boston Scientific in April 2023. Mr. Black has also served in senior finance leadership roles
for seven publicly traded companies, including as Executive Vice President and Chief Financial Officer of Alphatec Holdings, Inc., a medical
technology company. Previously, Mr. Black was Chief Financial Officer of Applied Proteomics, Inc., a proteomics-based diagnostics company,
and as Chief Financial Officer of AltheaDx, Inc., a pharmacogenetics diagnostics company. Mr. Black began his career in the audit practice
at EY. He is a member of the Board of Directors of Cellana, Inc., an algae bioproducts company, and received his B.S. in Business from
the University of Arizona.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&ldquo;I am thrilled to join this high-caliber leadership team and dynamic
organization,&rdquo; said Black. &ldquo;This team is building an exceptional company that will be the next great provider of solutions
to researchers around the world. There is a tremendous opportunity ahead to greatly impact patient lives and unlock shareholder value.
I am delighted to be a part of Standard BioTools as it continues to execute on its mission.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; background-color: white">As a material inducement for Mr. Black
to commence employment with Standard BioTools, on May 15, 2023, Mr. Black will receive an award of non-statutory stock options to purchase
400,000 shares of the Company&rsquo;s common stock (&ldquo;Option Award&rdquo;). The Option Award will have a 10-year term and an exercise
price per share equal to the closing price of the company&rsquo;s common stock as quoted on the Nasdaq Global Select Market on May 15,
2023. Subject to his</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; background-color: white"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; background-color: white">&nbsp;</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white">continued employment with the company through the applicable vesting dates, 25% of the shares subject to the Option
Award will vest on the first anniversary of the vesting commencement date, and the remaining 75% of the shares subject to the Option Award
will vest in roughly equal monthly installments thereafter. In addition, as a material inducement for Mr. Black to commence employment
with the company, on May 15, 2023 he will receive an award of restricted stock units valued at $400,000 (&ldquo;RSU Award&rdquo;) based
on the closing price of the company&rsquo;s common stock on May 15, 2023. &nbsp;Subject to his continued employment with the company,
25% of the shares underlying the RSU Award will vest on the first anniversary of the vesting commencement date and the remaining 75% of
the shares underlying the RSU Award will vest in roughly equal installments every three months thereafter until fully vested in May 2027.
The Option Award and RSU Award will be subject to the terms of the company&rsquo;s 2022 Inducement Equity Incentive Plan and the applicable
award agreements thereunder. In accordance with Nasdaq Listing Rule 5635(c)(4), a majority of the independent directors serving on the
company&rsquo;s Board of Directors approved Mr. Black&rsquo;s inducement awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; color: #0A0A0A"><B>About Standard BioTools Inc.</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><FONT STYLE="color: #0A0A0A">Standard BioTools
Inc. (Nasdaq: LAB), previously known as Fluidigm Corporation, is driven by a bold purpose &ndash;&nbsp;<I>Unleashing tools to accelerate
breakthroughs in human health</I>.&nbsp;Standard BioTools has an established portfolio of essential, standardized next-generation technologies
that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable
and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform
scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology,
plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research,
including oncology, immunology, and immunotherapy. Learn more at www.standardbio.com or connect with us on </FONT><FONT STYLE="color: #0563C1"><U>Twitter&reg;</U></FONT><FONT STYLE="color: #0A0A0A">,
</FONT><FONT STYLE="color: #0563C1"><U>Facebook&reg;</U></FONT><FONT STYLE="color: #0A0A0A">, </FONT><FONT STYLE="color: #0563C1"><U>LinkedIn</U></FONT><FONT STYLE="color: #0A0A0A">,
and </FONT><FONT STYLE="color: #0563C1"><U>YouTube&trade;</U></FONT><FONT STYLE="color: #0A0A0A">. Standard BioTools, the Standard BioTools
logo, Fluidigm, the Fluidigm logo, &ldquo;Unleashing tools to accelerate breakthroughs in human health,&rdquo; Hyperion, Hyperion XTi,
XTi, and X9 are trademarks and/or registered trademarks of&nbsp;Standard BioTools Inc.&nbsp;or its affiliates in&nbsp;the United States&nbsp;and/or
other countries. All other trademarks are the sole property of their respective owners. Standard BioTools&nbsp;products are provided
for&nbsp;<B>Research Use Only</B>. Not for use in diagnostic procedures. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; color: #0A0A0A"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; color: #0A0A0A"><B>Available Information</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="color: #0A0A0A">Standard BioTools&nbsp;uses
its website (</FONT><FONT STYLE="color: #0563C1"><U>standardbio.com</U></FONT><FONT STYLE="color: #0A0A0A">), investor site (</FONT><FONT STYLE="color: #0563C1"><U>investors.standardbio.com</U></FONT><FONT STYLE="color: #0A0A0A">),
corporate Twitter account (</FONT><FONT STYLE="color: #0563C1"><U>@Standard_BioT</U></FONT><FONT STYLE="color: #0A0A0A">), Facebook page
(</FONT><FONT STYLE="color: #0563C1"><U>facebook.com/StandardBioT</U></FONT><FONT STYLE="color: Black">),</FONT> and LinkedIn page (<FONT STYLE="color: #0563C1"><U>linkedin.com/company/standard-biotools</U></FONT><FONT STYLE="color: #0A0A0A">)
as channels of distribution of information about its products, its planned financial and other announcements, its attendance at upcoming
investor and industry conferences, and other matters. Such information may be deemed material information, and&nbsp;Standard BioTools&nbsp;may
use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Standard BioTools&rsquo;
website and its social media accounts in addition to following its press releases,&nbsp;SEC&nbsp;filings, public conference calls, and
webcasts.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; color: #0A0A0A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Investor Contacts</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Scott R. Greenstone, CFA</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: blue"><U>ir@standardbio.com</U>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Peter DeNardo&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">415 389 6400&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: blue"><U>ir@standardbio.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !. '$# 2(  A$! Q$!_\0
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M:JC]A.^\ 7GP/U;X>?M*?#CPSXE^#O@JY\'&]O=)M]1BU%)Y$=Y5B:[41GY
M "6^M:QI97R1:BN:UG=2M?DWTZ<SM\K[,GVV-N[R=O)J]N;_ ".ZL_\ @I_H
M)_8%\??%'4OAQI^C>//AYK%QX1U'PC(\<^_74F6!+:*94!DC=W4A@H) ; XR
M<?7/^"H*Q?\ !*>7X]67P\\,1^,M)U$:%K7AN]_=PZ7J*W8MIHG<+O&,JXR,
MX<9KF-<_X)=> /$_PC\'^"=2_: T^\TQ/&]S\0/'5^E[!;:CXMU2524>*2.8
M"T6.3#J '(V]<DFJ6L_\$L_!EI\%/C-\-]"^/V@+X,^*6M:=X@M(=:NDU*[T
MJ[A=&NVDF:Y4W'V@KDDA2/EY;'*CA\JTT^VGM*W+=)Q_.7>VE[Z \1CN_2VZ
MWWO^AM^#/^"I&N6D?QJT3Q5\.OA?<^*/A7X(7QM:WGA76!JFC7\3':+:63RU
M:*8'G'.1DX'&>@_9R_X*!^,+_P"(OP?TOXP?"3P-X<T'X\V'VCPEKGA[4#>Q
MI<^0LZVEU#)$K([1L,,I(R".Q(R=!_X)V?#WX3Z1\;/"OP\^+/P^\+?#?XSZ
M(UO+X?,5O*="U)H_+:YMYA.I\AAR8".">& P*L_LW_L56_A'XC?"O6OBM^T;
MX-^(.F?!&P-IX-T73;*TT>UM)?)6 7,[?:)&FD6-0%Z8.3SD@JI3RQPDXQ7W
M2O\ #TZ)\V]VU;8<:V,4DG)_>K;]>NQ]_00I;1+'&JI&@"JJC 4#H *?38I!
M,@=2&5@"K Y!'K3J^4/4"OA3]A,?;O\ @KS^UA<A0!$NDP'/7/E ?KL_E7W7
M7PG_ ,$V@-1_X*9?MB7>UF\G6-+M]Y_A_P"/L8_\A_I7'B?XM)>;_)GU?#^F
M7YC/_IU%??6IGW911178?*#)X$N87CD19(Y%*LK#(8'@@CN*_ 7_ (+;_P#!
M!34?@#XQUGXK?"'PY_;'P\U*1[[5M&LK;S+CPS(Q+.Z(!E[4G)XYBR<C8-P_
M?VD(R*];)\YKY=6]K1V>ZZ/^NC./&X*GB8<D_D^Q_%[!HMI/,BBVMOG8+GRA
MQDXK["_:&_X(^Q_ G4+*./QE8ZO%<^&==U^20Z*L(BETNQ6\>W&V9\^8KJ Q
MVE<Y*5^RW[<__!OO\#OVQ=0N]=TNRF^&OC"Z8R2:CH,:);W,AYW2VQ_=DD]6
M7:3R3D\U^<?[4/\ P;Q_M7^#-1:[T'Q8OQ:L;:W>RMY%U^>VU!;9QAH!%<OM
M$;*2&42[3R,8K]+P_%.&Q;BX5O9/6ZDM^VNVA\M4RBK13YH<_9K_ "/FSQQ_
MP3 T;X:Z%X(U+6O&$]O9^(M5T[1]4E3PME;6:_L4O+>2R+3J+Z)1*D<C@Q[&
MS@-C!O\ @O\ X)1Z1\0_''Q!TC2?&DTT7@[Q'<^$K2[;PK^[N;^VMIYY9+O;
M.PL[3_1W19B7))!*CD#B_BC^P[^TWX#M[#3_ !/\-?C$;;P]D6$0L+S4;;3.
M<GR##YD<7(S\A'/-<98?#'XS:5-JR6OAKXM6LFO!H]46'3-2C;4PQ+,MP H,
MH)))#YR237L1E5G"\,0F^_NVW_R_KJ<34(R]ZD_Q/5]&_P""5T>K_##P%K@\
M30QWGC&[T!+B-M!/V"T@UB[DMH##=^9MN)XC&6EB"KMS@,<&L_X"?\$PKKXR
MW/Q0L[V_F\/:K\/5<6EC/H)\S6F"SN-KRR11H"L#$+N:1@241PIK,^'O[$_[
M3OQ,T[2](T'X<?&6>PTZX^U:;;2V-[96=E,3GS8?/V11OGG>I!]Z^N_V?_\
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MIK_RK!_H?=E%%%=A\F%%%% !1110 4WRES]U?RIU% !THHHH **** "BBB@
MKY+_ ."8_P"S1XW^ /C[X^:GXRT$:(GCGQS<ZSI#"\M[G[7:/),RO^Z=BGWQ
M\K[6YZ5]:45G*DI3C-]/U/0PV95:&%K82"7+5Y;[W]U\RMKWWNF%%%%:'GG_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  S ((# 2(  A$! Q$!_\0
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MBUU75?#EYXMU/6M \2:>+B-+NUEL[V>9(I&@>3RY8/+=9%0Y(R#]U4 %%%%
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=** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 B17AI9@  34T *@    @  0$2  ,
M   !  $       #_VP!#  (! 0(! 0(" @(" @(" P4# P,# P8$! ,%!P8'
M!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_VP!# 0(" @,#
M P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# S_P  1"  T )X# 2(  A$! Q$!_\0 'P   04! 0$!
M 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%! 0   %] 0(#
M  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*%A<8&1HE)B<H
M*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M+XX?$+QS<?\ "??"/PG\.?":V;-!+'XY.M:Q+<[DV(]O%9) D>W>2PN7((4
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7 "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>lab-20230510.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aUpo7xRiXgOn8uPbnQsSayCubPtzpFzyekhu2B3fZm6Ly8nA6932C0ESMYmAe4K -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/srt-sup/2022q3" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:LAB="http://sb.com/20230510" elementFormDefault="qualified" targetNamespace="http://sb.com/20230510">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://sb.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="lab-20230510_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="lab-20230510_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap-sup/2022q3" schemaLocation="https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/srt-sup/2022q3" schemaLocation="https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
    <import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
    <import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>lab-20230510_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>lab-20230510_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://sb.com/role/Cover" xlink:href="lab-20230510.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://sb.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140619458505408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>May 10, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 10,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-34180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Standard BioTools Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001162194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">77-0513190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2 Tower Place<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 2000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">266-6000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LAB<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>eh230358911_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="lab-20230510.xsd" xlink:type="simple"/>
    <context id="From2023-05-10to2023-05-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001162194</identifier>
        </entity>
        <period>
            <startDate>2023-05-10</startDate>
            <endDate>2023-05-10</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2023-05-10to2023-05-10">0001162194</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2023-05-10to2023-05-10">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2023-05-10to2023-05-10">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2023-05-10to2023-05-10">2023-05-10</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2023-05-10to2023-05-10">Standard BioTools Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2023-05-10to2023-05-10">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2023-05-10to2023-05-10">001-34180</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2023-05-10to2023-05-10">77-0513190</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2023-05-10to2023-05-10">2 Tower Place</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2023-05-10to2023-05-10">Suite 2000</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2023-05-10to2023-05-10">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2023-05-10to2023-05-10">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2023-05-10to2023-05-10">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2023-05-10to2023-05-10">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2023-05-10to2023-05-10">266-6000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2023-05-10to2023-05-10">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2023-05-10to2023-05-10">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2023-05-10to2023-05-10">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2023-05-10to2023-05-10">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2023-05-10to2023-05-10">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-05-10to2023-05-10">LAB</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-05-10to2023-05-10">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2023-05-10to2023-05-10">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>14
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( ,^)KU8'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " #/B:]6W?#W&>\    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M3L,P#(9?!>7>NFG9#E&7"]-.("$Q"<0M2KPMHFFBQ*C=V].&K1."!^ 8^\_G
MSY);'83V$9^C#QC)8KH;7=<GH<.&G8B" $CZA$ZE<DKT4_/@HU,T/>,1@M(?
MZHA05]4:')(RBA3,P"(L1"9;HX6.J,C'"][H!1\^8Y=A1@-VZ+"G!+SDP.0\
M,9S'KH4;8(811I>^"V@68J[^B<T=8)?DF.R2&H:A')J<FW;@\/;T^)+7+6R?
M2/4:IU_)"CH'W+#KY-?F8;O?,5E7=5-4JX*O]C47_%[4Z_?9]8??3=AY8P_V
M'QM?!64+O^Y"?@%02P,$%     @ SXFO5IE<G",0!@  G"<  !,   !X;"]T
M:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M
M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R
M>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2P]R"BPA+>!3+
MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2
MBW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K
M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
M.7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7<LW(QU2ODRG8
M.9_ [/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD6R4)RU3393>*
M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W<DOJMI2^M28X
M2O2QS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-MNIW<.CB>F)&Y
M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_#
M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0
MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR
ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC
MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYN<KGHB=OJ7
M=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(CE1P&%A<RY%#N
MDI &$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>TB42%(JP# 4A
M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF
M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y,M\Y<-LZW@->
MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_
M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]!
MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M>ZC+N.HL?X;[:)'-M[#/)73)>UYN1]76^T$D7O!9QP<<GB-WPQ-',)^ Q1'
ML#P8 \PG>&%Y_J?]K-#]! SCMHHB*]1GA?H$KQBR'3Y8GKA/[I_X3O,\3;,,
MJ^AV&V6PQ>J69? 7CX9Q P\L#V1Z6ZWQ;N,3\OH<8#U];4*PG>*3B.T4KS4@
M\;J!1Y['NXWE 0^L"]CL0/YX'IBIN$^:0E<Q;M@)QI$\QQ"8Q?B,9AE2G0P^
M\?Y@IR1-\SR. !9GD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$
M%     @ SXFO5I>*NQS     $P(   L   !?<F5L<R\N<F5L<YV2N6[#, Q
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MOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @ SXFO5@=!36*!    L0   !
M             ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #/
MB:]6W?#W&>\    K @  $0              @ &O    9&]C4')O<',O8V]R
M92YX;6Q02P$"% ,4    " #/B:]6F5R<(Q &  "<)P  $P
M@ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( ,^)KU;6!V5V
M5 0  !@1   8              " @0X(  !X;"]W;W)K<VAE971S+W-H965T
M,2YX;6Q02P$"% ,4    " #/B:]6GZ ;\+$"  #B#   #0
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:+GAM;%!+!08     "0 ) #X"  #L$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="eh230358911_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sb.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="eh230358911_8k.htm">eh230358911_8k.htm</File>
    <File>eh230358911_ex1001.htm</File>
    <File>eh230358911_ex1002.htm</File>
    <File>eh230358911_ex1003.htm</File>
    <File>eh230358911_ex9901.htm</File>
    <File>lab-20230510.xsd</File>
    <File>lab-20230510_lab.xml</File>
    <File>lab-20230510_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>19
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "eh230358911_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 23
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "eh230358911_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "lab-20230510_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lab-20230510_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "lab-20230510.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "LAB",
   "nsuri": "http://sb.com/20230510",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "eh230358911_8k.htm",
      "contextRef": "From2023-05-10to2023-05-10",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://sb.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "eh230358911_8k.htm",
      "contextRef": "From2023-05-10to2023-05-10",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sb.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sb.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sb.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sb.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sb.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sb.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sb.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sb.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sb.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sb.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sb.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sb.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sb.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sb.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sb.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sb.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sb.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sb.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sb.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sb.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sb.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sb.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sb.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sb.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sb.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sb.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sb.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sb.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sb.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sb.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sb.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sb.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sb.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sb.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sb.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sb.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sb.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sb.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sb.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sb.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sb.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sb.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sb.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sb.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sb.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sb.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sb.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sb.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sb.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sb.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sb.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sb.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sb.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sb.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sb.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sb.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sb.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sb.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>20
<FILENAME>0000950142-23-001458-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950142-23-001458-xbrl.zip
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M&!F90P59\%E#Y?$:CIDBE:=;M>J]\Z/S_=Y8AAG!5"\&F#YS/><!.3%N1Q:
M,[-WP"SZ"!9H0;E],<4JOX)B!S&*'7*+P?(ZS$LFS^77>U<<&%]_NG=+4YJ3
M.3$%4<R6*\6MPEOC^I=(QV$,UY=T=*SS*X;DO'F(%X,->GY%MZK=SM(0GP)
M9F]S$[H4R\7:HF1XN:EZ8PLDA9DX'G'\/O/([=#CPN0&+I8$$0*8)AY5 !_F
M,M@; ]QP!@,N1!0^E ^B2/-+03O.M7+M'&D.7,L9 S(#^.(\1,Z<W)O:\+C<
MW@X%S#U^O6'_?3SN6&I']WX-PD@AM_5$9#JMJ.HQ154W38\)H7^<<IL5DY74
M]U&W<%[[_GAUL;$T)94P>6:O1"Z=1V#!"\!=FEE>GTFIU)Y852EY5;7S[B9U
M+]ON\?)L7L+D$"T,.2BK4J$P7^VZOX@IJDGH:\"OYQY0PTY&'J?7#QN5AG/Q
MH[ALY$VF!M0Y0[^//C@YA ##X,)P%F:+0M*ZI.$X]R[ :P3CD.*L?CLZ.*J>
M=4J%)G\_9S49P,Q> R@(@]F<IJQ\9N$'20N_<  "ZP=WTWWTD](9+S=Z%X>-
MVV73-#9[9J]6*3SA"KK_5V)EC0 ,E%T/*,I=:A$V8L;0YP\8/X.!9>(#60/D
M$,1.BI%]U_4'1O=5$"PM _7F_OQ:FIU$553W&$V7F<W3J_IU]]B^?EQ&MBDZ
M7V9OHYHF(Q]F9+ZD(3YU@"X7?<>>&^[]J/6K76%<_OUM:PE03\\)=GQC([OQ
ME+W[Y5R^1"F?) C_]8^M4G%S1Y!+9C$7D:)]_'7,$5I#]%$)TOB/L+\OA+\+
MJQR"8P N[IG,GGI$VX=UPKNDT:=VCYFDC9:?G%+ADY;<S/D- J\WF*'19\ D
M$, 3ZH)G!.81@_J.,R(=9CF/B!%\B0@C6]D3TN46",_J"A<0V/O,-@%5OD,$
M'PPMG]K,&0IK3 2$JZ([EEU5#^)T8&85Q3IJS$C.>@CC>(3:X^!=%\) YQ'[
MH;O&,687VV^)A__^W+4>O/37$RM,RF[HOM-)TK!OFJ6[]K@/3(")E:&MDQ0B
MV=QYHY.SH[^;FU>/Q<QR?(;7[X-V',=BU)9E;%%CFK@LQ&!MLU+9236H<S!;
M>P*URT"(AAHP$06;N$-/#%'(0$RQJ(142E4M<"AI;?""H2.'J>J&3]:*FZ1Q
MV") MAPT7))M?#9#+KW#KX9]B;YRBBRVP<@;0$B[]P54..JAE%V@T=%0E+WC
MXE'W385H%IZG)6C!!.P;8'4"+9@*!>ZLY!0K-%LL182G.3*DNQ 7G4HAIUK^
M/Y:>Q.EF>+>L>??"8ZALL817UD>A7^&==[NI.S;77[]^*X_[)_7:"XS)F[)]
M^E*>9T"6R-L 4M:(P/2DA2A6S&QIK?,AA=,5::/_ NNK7X#_U2]*"-0PKQ2#
M9%9ZZN%R6?8M%/=!,O,?"S%DWI,B4+ZNWA[Y_L]V@;TG/\] ]R*E_DN9N\RR
ME35C$>:.:73=[7UK:%XW6,2W4\$6\R!<BV($6LB0K"C%70=?@(7EQ%K_76&5
MRIN\?%.QLOD>=0^7>'Y.@2C+3HT^,2PJQ)/5&P&64H"<YQXLNJNZ]2X(\*@I
M4Q (9'L\Z#C6FOCP&RR_7%[.GG+JIN&9+O:31&>!S@+I?>QS>#(1\25MW[PQ
M*16UEJ!DTDJ!M/H;%TL=*34I95=GMUN;OG>P05]>%1>)>J;FS.RA]00:M7W'
MN%LG_RSD"H4B<:E''J@U3*][<^71F$5+419U[M^ C%/(W]#(UV*J!#1E!^21
M=O=KF_3DZ\O+VB>8CTV8V3NM[[\VS/S]D%N=XNS <4FOQ':[Y0WCJ'O]\VMO
M:=OHJ'IF=]"38,J SA(FO2='EM.!B+K-+' XR!?JW3%_ ?*\49J=VUA6M7Q_
MZ]@VT>]DI#,FADRLP\L[4,],5LA-);VY($!<<%JQ?X_T/.?1[Z/["LL?KZY0
M04S6Y;:JXE:9NT(U\-&FTG;PM%@KE\D:KF=S1V;O@L9<UG^[6/^-FQW*"2YU
MLJ6$L6()#35H974E&!7=X$G'R+BY ('OX?_.=P93:0VN(=AMP#+X_>@>.MXV
M&DX\VO)"@<WL-37Q5E?BU",!$[]TX&G!+\;*28)IC^2D#35G2IC8I\7+D^OR
MCU;_3</$.8 M'"&^1<3Q"@9Z!5\<=Z.B/<T=ZR#0B8J"SVR,]4$+2)T)6L!V
M9,@V%$RV LKI[3>\3H7+,$Z=T$:"R;FL,2J61PY32Y5B [SPRF,/7$!'4"Y8
MSP5ZF1KR$A!L+?2Q&J%VWLRT@+&\1L. ,:HU<J_F_9!;GF:+)5#R&A:-?H,@
MI0GSO/_,TW.^]T'F2#B3&.Z4W#<XR/S_C9*(A1U@\_LA9JM@?H42Z5+.4F>:
M *.  %&Z;V!)]13E-Z3K.,FU1',KT[F7^)2S69.I[,JLASHWJ(R'LA;KRA[3
M,;D,G*.IV]D6J<=W4MI/'T'Q>*_OSVYI!&YE< ?!#"4\1N^R'08*%5;L2O(M
MAOW9P_I147'C,T;%)2HID[^OC9"7?D!:53$GG\-=@-\6GS'&?E'<EW/E:@+Z
M"T_QI+R;9X9CI(9,9J8BM^5JCWTV(-5<H:26K=K*,^$,PGE_Z,GDS 'WP$0Z
MGD!+VX#I*7COY[+"U!,[I&EI QIMND/JKNMPV\<$MCPT,]L1G2EF"[R 8PPZ
MRT-[B\UE5>MT\]P$Q"B;OYKJN4)5%;:_!4O%!W^CL^23K6.^%T&Z1&*?LR[(
M8> 4:63B=25O"LG;%WF=VT2>WJ^JT_O0+_'L-%E#9PZ+)TN%'>V\RT_%G0\0
MC]HV^(@&.IRJ6BR*N\^LV_78F!SEE+E:)ZC&JI5U/(Z<AECM/38"KQC&0.%X
M8-@)7D9ASKU?>+#X8%\\O5PBF/< F &XV\SF(/G?8(7DPF-"7O,$[K<Y!PVK
M*W47"]Y(TS8=,?1Z#&0<*0+H ^^[8W'#&A,+L[LF&3",'2R@M-&W(8SMC<.H
ML^L80W3L0;TP',EP7 CS,/= 78SN8QY,:C0,Q@XB%@H1"%*8 0_9,!T$BR97
M6VJX&'SCX547\ 2! 4,9,H/3@67[X_!02!=B2U(?]H =D99%@J&&!3K/@W\5
M0S[VF4TT$AX!B]2X'X)V-%=7($+:=X2/&52#Z\-P.< L(AGBD5N 45;SRK[K
M!/AI0HMF6.+_+'*0NN7V(3HSR"?'DG[=^NK*Z\B!?(Z$54VCR!*N1*_)A73!
MA$;7%^H9?4!.<1-7&:*JF%M=F5V[!G>=3!CR\86LB);(PIL#+CS'9\Z &V)]
MPHKALRS>OPG4,3GMV4 >>#2);E\VKP4XH@>CR&Q]Z@VHX?28S>0$B9/!L*LK
M+YKQ&]X9QX<#4$#A^50<#Z-S8%59 M3ASBQA<Q$\=U@/>LA<&/48 \FA/FEZ
M-K#ZO^@ '."_0<)ZY/3T(MH+4W_ .5B2'FC!CH/Z&#Z8$P<"#3NXX38-D )B
M EY&P.,">1PB;QX.0H<@HW(''$L!&3#+9$X8E7$4# 1V'T^;@L.P/Q3<QJ,Q
MDNEPB"N;RTMZ?5F+"\'13Q#PWU#[SDGG74Z,"I%Q@DRA@L!0=+NZ@'.+ 7H\
MF1F)HFA-VSY9V$!.9:/  ,:R(&K##:9YY!8P"5M0LU);(8#Z6>RH/C!UYI=)
MOR]B#T')16;$%U&PUL/9-5UQ<6"BA\BT()M$4(MZDH;_K( 1+10*4AX 5@;>
M 4=?'89-Z.S80[&ZHI)&Q =T,Q_P]< L'*M:_0M_]&7N>GJR=500($> ;JD>
M4/%A2U/?D=0'SIZDAY; !,52<,PR%>5U*6E!11]*MBX3P1Q92/G5%<!%4$5"
M%$5D*XF&F).2A/9'+;H"]_B(XRHS"4,"SX!\"LS<%R0)]+6C<4J'QU4,N56X
MNJ+&";E1CD?J.$O C3F"3!Y]HZ#J4P0)D)C%>YW *'D#27;,1HZ89W" !6P)
M+-+%2RL1&L+ND8Z:QPS+$:KL'AI-L^04H'J]H(3NAXX_,71S]GR@B>+ZF&]'
MVL/.+38"(*0J=3 7.801)Z30+!F!!GX'BO?Z@3\*9EF&H _29>E)M@.>*2F6
ME19885],9O,3L8@C!(OI<D^@*5%J$;@\1$HP3ZSZ"">51DEG<@=4V>C-%T(!
M.EHN$AP.12=Y;Q=\DM>.6Y8, 8%]T3#0+M [!Z:"8 "NS=D<_M>4"(1 ?7R%
M((#M"R0!%@@&5*:M%9/@=9!";7D#-^HJJW]JL=#55IK?6^VK.+-/M,D,AZ9(
MTNI*C$-?S'0)RYYE)UE'IE+M^#0$7Z)G=64N,Y&G>&DA5IH+@1Q[=66&D:(,
MA+?6>5*@&%,<)LB$I;2_WAU:T!E'D_9T@E) YV9N01,(:FMU)<;KN, IB#ML
M6CI0D:6J37FK]_&$M9L0._@R@,)X 5CSPI+VS9S2% &_TAXL6^%!+EJB,_>^
M=BKJLU!+.'''!64'5EE876GHHA]P#0$,S['DNMI(/_P2 K74"XI9+^ZJXU;U
M8'FA15FL>2A^4@A"-;&NW29%$J 3[ACYH%V .?#N,29U"_10]95!.F$!N/6$
MJ/-2R%Q$#V.$=W7C#8;2*G2Y!5A2 5*QLJZ"I'<D&J:&>XZT-TP8'M?&7[.J
M=-E65Y3/%K+@@N1"XXRB&E[E!GW!UT>F]A@P.(3&X<W7@:"@D,HD4 R"P&D$
MC@<5XTJUHWQ84'P*@S)<[O,.U[JY6,@5"4J#[TSL62B&JC,".+G>!]V^*$38
MF=OK*:N&.#9YV1CZ/0DC4#)76@9X[\DJ84PR<D&U20=12OE$QG&G75^:9+*!
M/;GX)U11TF^=A(BX\NF+#.!Q(+&*E('8ZBI!F5D1<4_*"6<<2T#"&3#OESB%
MW&/6:6=<D"T0,3P\7DU]Z&ZSL=#R2[H,&]P.S9Y4M1 L,)M:6'6RCCO13"T&
MU(=O:?8?X)XTGC,UAEZ0"Z(A:)A?5VYM'#04%*E%=9[=0YUA,*:@\KAT'IQA
M(" @4!A,XP40,NUHI_D449S H DH08!$!,+U$*3PDJPN!RO%M>&7YUWEXR!C
MY'B*(T";"38)-!$:\-<%[O"K37D1 BT3#DG@(J'!5B\K=-_E8?2^I'3XU([J
M/-$!049AMAVBMEQA<9:J[^]S%U#08?XC8_84R^O(9QQCF5E^F4Y#!]HD$ ZL
MP<#:BZE4PE@57B@V$Y-<0A0 OT^5&E?W <OP))I'D%M*E4)%UU*T6&^HUJ4&
M:6=/]'#-D<%<>;>GLC(=U(8=YP%B#3^*'AK9&))L*HVPK.F0^]-/($IQHV(U
MD9+QD#9>EZ3 BPY+Y+ZIO!OX? K;RW2K%N:@Q8L!GC$S;N*^9HAPKVM2.C>G
M5*#TIU3@3ZG G%*!_X("@?>0])F=SJ@BYWAVS40?V)7708$189B< P<>PL @
M>I[:V8QK2I5WFW&RX^-A<M3WJ=%/<*MKM="MSJVNX&#<#K\*#5V7P,&--,0!
M.PSAZPX]FPLY+OI*?0BZI&D")6RB?QAH9!UT2:\YB*K080.-[CI")2!U)9_V
M]K?"M-83U< JI310I8?1#>/X(3H5.JZ'GL\C.C130;W%:8=;>J=!FDJA8((X
MQ78\O3XQQ! @@J3)8M.=>^T#ZKM'4F\[T&73T35)D*-%C:LKT'(=S]MH"PS>
M+I(;KSD)8UV87%^Z;<2AD-!3#<B2C=]2][+!OXO5L:1LG"W+^UL@9#K&JRQL
M6]?+A)FX6?E<7=%>3&JIP3KYQN\\.B"?G5[HHEAXMX])9=9B 1<FW#I$#T@J
MF4J023Q4.[;CU95 \>B4V><AA!,U_8C+DG\5_,DJ"F!XS*H 3$$F%5-\JG)8
M[0E-^:9!9@2_X$^*,+(<0%8W'W#[>%V[F;+D6,M8\J(F&^.!6T;JP:;8)-0T
MI5Q%O_=!KCWF!P<.911*U$UZ8?+L@%0/.@4RFUV2> C#FJZ6OLD%0"),&W28
MS;H0G6X3])>I"&)9*?LI&:."OM!)556EII[6B4%%/V&NR>Z(3KOJA85S)&Z#
M494]CH.%O<,D\^I*GT'TBS7A."6H3:6D&N?[K;K$@@TQL<[%JI@$' QPRZ6K
M!N&KB]>SREF"2'!'ML)SO-0 WXTIM1ADEO'<H,R+:A,6I*U65R)YJX#?IHF%
MC!O+1$G,/"L/-3WD3)I'WBF5FHLJ_S;)GJ4KWM^VCO(UUU"%]92I!W&C596U
M7*$8EBQ&;@GH[$W4;SO(^:I$D6:0Z5+'^&&QW] OAK]H^^;8O37S0W1UKSPZ
M_QRV>/KL_/,/1R>&>@&3Y&J2"V8*ZZ>.? <^L;K$\<FCWAHA(4S%R+7CA9QD
MO-<<]YZ.4V?7&-PD\.3"Y!'AE/5$CFW/PI@HB_.GPX1^\F4<\Y#Q@HEV*5'?
MX\GZI7*A7-VJ%8LW; 0L5LSU?4#+>;0&IS/6=2G*CTBI3,4F6&.*NY1!C:E.
MY4VY*+MY^D[8+)$EH7,)=P;,PWI)83T%LQ$?Z86[BE,4G"&3'"IY\ED/4Y'/
M?6O:E7^Q))0534ZG7>[%I6$2T*1B\<V% ',4OQ*1M5J@4BYB"1@,C9YDN.H[
MZXO*.V!JCE?1P#A#II4!$\!T5%7:R^\OE-^"LH;EJ"9F=3#4UI'FL6UA&/)]
MOW5*3/V]@$E?E/)>KM>?)/F?)/DO2Y*_QY?MMH^/SNJ75ZUF>UD1A\JTJ?]!
M44[5%.L42GB2+)XD75U)3@$GG%(WA]:8&%0>>)!W0^AO2%4):0'K5"5\F#GH
ML#ZUND%Z1&U1J@:J_ KZR.'HT.\['DB'^5M&[K_CY68+&I%$JP.#H6+_F"EE
MTCJ'D<VK=7O[LGYV4&\=D/WC\\OS\].V@F/1/\=GC5SLFJLG+X%,S414"W_-
M#PB#=HLU*R_8KC@U[5)<CI=>-(1NP';@%ZG)E7,T)\Q>/.I]*53[X^T703 =
M4$TY !WI !1RF]7$[T9X3B8'H<R+//E$[5L'HR*+C<@)'[R&+1<7V"?0\)(^
MKQ3L/WA0>%#;+.<N)N$Q^Q[NGBV&CC>Y[:JT5<Y5U<U[O[TM_8T&6^0BC_*.
M/K\AMM57AOR)0WZ_..2=HX)7-<EW''.,\I_O^P-K+\Y];0:\@=?K;9.1.=HA
MQP?REYO"UOZ-O!5*?EV*6I[LQSZ/#F^_%4X>;^M?^\W\U_/QJ'HX*#7X0Z?E
M\,_7=^U33C=;G4:G\P-X,=_*GUR/^C]&U]_X]>"Z=L0_5_\NB,]7XT\-H]JR
MA;BNW&^V#L>GGS^U[-MFI>!?;?2^[_]\V+^UK[\]=!]NMQY=8[_W=_-'[?RR
M<NATOK-;XPNOM^\^T=O/7QN#DQ\')^RQ5+EU[C?,NW;QO%>[^O'=.2KLGV_0
MHX/OWIDWKO:]:NWN_OM&\=M7\^['%C\:?MHTQM>UK^);^]'M^/]N'FZ9/P[O
M[AVKLGGWK3<N_W ??AK%ZOW@D/W=*FU\/^[^^RSOU#]]^_SYJO?QHT+)_P)0
M2P,$%     @ SXFO5N*[._#6$0  17,  !8   !E:#(S,#,U.#DQ,5]E>#$P
M,#$N:'1M[5UM<]LV$OZN&?T'G.^2:V<H6;;C-+5=S\@O2=QQ:D^LMI=/-R )
MB4A(@@% *[I??[L+D*)DU8E3.XD4>1++HDA@ >P^V'VP@ Y>#EZ='[9;!R]/
M^R?PRO#G8' V.#\]/-ATK_#IIO_XX.CBY V[&KPY/_UE8ZARN\>V>H5E YD)
MPWX38_9:93P/W(6 70DMAQOP(#QZ63V7<3V2^1[K;4 5EW,??FJA^ZPNIK#[
MS(H/ML-3.8(+6HX2"V4_O_AMT"RV,^293"=[K*\E3P/V4J37PLJ(0Y$\-QTO
M[,'1X>E_7IX=G0W:K:U>=^M@\PCDQ,(>5MRCP\=Y:(I]5]^#5G1O56S4,OO"
M!OVC\U-V?'I^?MD_.3G[[<4O&[T->G]UV3^NWOL*0Z5CH3N12E->&+''JK_V
MV:?+,I:Q3?#6WB-4M(/!ZZKX:Z%Q=-.J_585LQV2BJ'=(*4_&)Q43U7E[4)Q
M!V>O7K"KU\>_;*1JI+IOB]$&ZY\/?ME S1V<S#\Z7W8MW+/=1_ML7IQ,QG$J
MH*0YP^B G-"U52]W0F6MRIRY?)9*N][L&/D_X;IT'SM:Z3UVE/+H'3;S\%<E
M<V_]G_C#<R;S7%US*Z\%="O/6*SASYR%$\99J-*874LC5<X>YS$W"2C)6=.0
M%BK>,71.J.5?MJ32O%VXM^?^UZWYYY,GNSM/^P_9366>"FB*S$=WZRRK5&K@
M-^-1)%*AN14LU(*_LXE6Y2@QT)<L*4&]62)X:I/YOD)M@U^O_XZ&U[8ZU=SF
MI:KX3;+A^\"&OP\QWA9P+.:MH; WP.<K5O-I>GMK/;,C][8T5@XG]Z;,&X>O
M^*3=^CE@V[WMG4^9S^ZA2?<H?34&7T3NAQZ*7\5PV&X1K*Q(BYYL[6RW6R^X
M'DH!P']EM1!V1=IVS'5J0AX'[=9QG_V\W>L]6Y&6K911G0BNVRTTK;T5:=%*
M#<^?HMWB6K "/2@1HS.DAD.AV425S";P@3+2HKNHANS@]\,KD4NEV1\R$NQ2
M"R-CD5OP.F-VG$@Q9,]ESO,(1& 7PR'<I \V?S\$A]LF@#YP&]<Q.Y)J0)[7
M61X%3(M"@;^$OAM4_DI&"1<I.QTE*LT"7^KI!Q&5Y-'Z4JG&NOXN>P/2CF6:
MLD+HH=(9&RO]CL7P#+@90ZTR;(]FB<H$^G0U=M 0P0.YY%W6CV-J*D_3":#*
MI"HS%$Q\*$1D7?]8S:]!0NPIZ"#-4A5Q?,QYDM8*$"T#G(4F&91S$_HK4GE<
M1I:%I9&Y, 9:?2W%F!Q,[&4(N:#C] 1N++41V-DD\%L5MEO0S **EZ%,)3:H
MN_83OJK-G-EV2^+0@EJ ,M1C9\&'A;OU34WOL@L83"NB)(?8931A\+C("C6&
M&O(1BT!$T$Q-&B2S0BO0=-!+@4$;OI,QWK8@7&FW;HU7NNQ/U/=K"8$-&;0"
MC8)[.(0@G,ITI8,6@\;)/):F$+GA8>KK-Y$4>21,57?"+<I>"X!%C%(5\I34
M%+ ^2AB 15:F5@*FH.WEH+-ZK;1?66G[H+0W]#)@8\$0_L-2IJ0/W ,^*& $
M8UC"9V, .4 D4.!"*!S3"/0K5H1;H3#682WH#UR0 '50'HQW .J$2"P 9!&L
MX5U:HB[%H+,3*BY24.XUA\OF2_D&BSKTXT-^)_JLP7S-$&9WDGXAS70KP^!8
MMGF^K-?=E;FGQ19]NNT^OKU/PC)-IWTR6]+#*NW!T>&QQ\:[,3O'*LNDS= W
M0%8581#5/*++?AZ/!4SCJD"M?U]"$^R$&966]52.<[C3TPJ>'VOSOE3[=Q.E
MS#,H)Q<B;F#@I_)&?E3K;O^FA^HLMV*DH1^[=^LA'"$8H+)(D)U$6$GD*$%D
M,1ZP#,Y30_";*N\,_3Q3_>W@Q8HT!1^MQ&LKWM&OP2&$IGY>-YM$C9EV)9"W
M(CC.V>C*!@Z-&1@&N#/7"CQMU[LB"S4'CS^&>4'#] "=+MZ7] H?WTT,F4=I
MB0.YXH-TC(Y/7JK2W*U_SIS_-X-=0V4L!CWUG RS;5277[F,^(AST8CR-ZPD
M'(.I.A0 >G>$4*<$,5]@3!\EH]=^W(,&[(DJG#^/<QJ'4.)#)'%2XZ$J40/
M0U<%1M5ECK,:W.'=O%BDN-KHYK\$PE@J!8-["D]XMO;2O^[H#A(8WJ%*4S5&
MOP1#+6;*+,/PTGG8((#.B%<@4D$Z=X4^PV%'[@:\^D0"IA-YP8LBG>!P$Y\
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M?CX+].!MFUH]KG& U!*97XO6B<&7+# CQB]1S&OO*;D20C#J'7:9\ASU5L!
MXONJ5%.&;S'2)-HZD<*'*6!Z?JF&;$3131BTH#S>7CA%\[X\GJDRIV)"]&/1
M"Y*Y,\.&="BLM&"STD1:D+FP@8(05^>4_00E!>3S9C V8,L9AP><4P1ES5MJ
MN^6)=;H84WH0%@&(0FMF8.N!\Z[1T3+H41.=K[*,F,X;/A=B#J"FQB4T:,F5
M*"R$UH!^.[T*O@ VW'H/T;&AT[P".K?N^&:_3:!E7?8<"RTU((0@5Q"P% )%
MQ\YCI[@>!)S!\ !;C_T1..DL*?5L)]/8>? 'Z(4.W]U]U&Y5BU)3D!1^:@AJ
M-([\.% 18^XF$EK$P.6*F&%+*@S%+D% 3;F/2-P:G=2^KY&<P#+1Y6FVNMVB
M9J\(#H+D_^ATV'/,T-ACEWPD]D$QWA-7#@^R3L<G !^<G/VQ*"?QZ0*YZ9I/
MY*RN46(+VRX^(,TI8R24[RDM] ;E/0N@=\Z,N\E4[^P\VIC)BKMYQY./WC%?
M1I/*.-B$WEW0T;2\U@D%Z!XTJ*#1^83.OYD_>B-I;:;&A@9LH@JX47](I;ZO
M)+W9E,)UHO$ZT7B=:'SC9YUH_" 9P%^!0_SVQ5ZJR.J45I':K?Z8Z_CVR.H.
M*+$P"/M:D57-I["1YB[R,5:!)Z:*>JD9G/<H07?Z2:]';(1)(, @7_YFUMRQ
M D]?$X-1QP2XW@U(>T4%AY3)Y[D2J@LB"(T9>]PZ)SU5+L<,NN =./]-;G$N
M#8[567#3=N2@_>2EUPUZ+8R%"M"-=R+\GF,41JN),=;Z+]^P=NOWJQ,O8%EX
M$=VB(Q1SWC_R??-)@K[!<,')L"#:G'+E\#S%8:1KN/X(<0>TQ(55%+D4X!!'
MF"HX4H"I.64U8;GT[/QSC*.RWI+0M%P<P$>P[Y;&?,.X<B1R,005O#=(^58H
M6N0=FD1-996+&)HJ>P(,P_4&Q"_1.XPN'&<9E5J#2J<3MR8?@_YG(D:'(F"8
M5HNOSH4+*!O01?FQ-)PR40&V96Y*341$546755T_S9T=#AVW@Y!$(3Y%]V!9
M"")-O*E+(5:E2>MD'/^_$PU"F%]SF6*F(N4-8X6>QZDR?BD=$X$ 7H-:FHS'
M8OJL9QT:"<0H,)BY31TEL8 (>YZ*#]3]?W"7^$O<%PS-E @B%CC!*)M/9ALR
MHH7Y&P+7S0H6D<<5J5+!U'<"/<NY<O>G@JFJD2O67#5B9Y7!K!(PT:)UI> ^
MH1@7KE%MM4B@\6C\XYE^F5V(F>((/ XS;X8.0*[@)D-S>6TH?F6DNBO"Z=HP
M1_R^+35 DM(,S)AR[ VTE!-)["UWFES?X&0I8<8SD@T !(%&^!<2MHDRA00X
M9!9B-I=5.!U)3'C54D"<>*G%4 "DQNV6)\=!MA<0X!6LPRXOV-'%?]BSW6<[
MSZ@_V8D4(Q4PVKRT]>QIP(I$Y8+E)3'"/SQ[^O1']N2G[<[/3WO;:XO_5I6?
MUH7S(>U#D=Q-B[0=QMO#I<?L53)XOP%"9IACQ-VJ#)BD1<_;)79/.\2G@3L[
M)U];*PA&A,459;@LL&I:.-)$LM+4SZ>Y+7/6VMR44RW%D@-@H*VW>T%]V_D3
MGSRM2P/C:TIZ-I4T@#?7>!D$Z!LLV]V/#>CK4%H7?['^2(LJ5>_[,=!ET5.7
MMG$$3N\(4!@357'\"*4%(7<BHG>F3N5P<XO;_@9_N 3+$6H=A:JFC"*85H9E
M2DD-H!40)I(_&]8UL$45?%>ZL6S@/46#=JM?VD1I^;]FAL]*&,)SI=NMY@KQ
M4,08;P"$9W+DL8RR61;AJX=W=.LJ8J6:W6(5E=AW".8";Z#%?+].[( 5$U Q
MA9R"5A\W4MKY%-2]>X:D$3%(F+/395<EQ*AU!20BK=J'HI*&)*-< YM &3O3
M[944=U5R-,/- /VYV55YW+F6NAV<B2PHU P==21S7)G^3LQW.8F>"]RWL$HI
M.3@'8:K%T.W);%@);7-I)DP0N4G&*CX4TN7>N2F/>-+M*EG4S6[?B1HO%S"[
MT4YI>P:2_@YX<3.3AM 91QF<"OAHNDT=8=K1529198KD'A'2P@6R"[.\9Q*D
M#.750'"-.X#D4&)2#N5A.N\(O!YHI"TQ;?)Q&J,/S1V__EC3NT;I7?"-P5>'
MN+E,;5#O2!B"3^RX27+*N:4 W=%P6#>^@T#:N&PH+XV[ *@OH2.YIAWX\W+[
M<D%$HBL;'!JU=0;&J>$D4;-ZN@H5XBLF0T6\- *#><8]"QG,\X[M5I1P< -=
MUS9IB\ ?,( A2Q4BF(#-;]</ZA,"ZAFIRN6DV0CK<2<)_%5J?W.N:C2'%I1C
M5,IJ6B9)T2VE[8;5PD<\R4$[HZI1WPD0+%=CSG*G[N+:9T>2=R5-4:+O GJ7
M<IEY#:>C $ASM*0@!#6Y6N1:; [>.'V27J7=?$06A;B!R ,!3M)N^4K-%(Y<
MQ(,/#R6M"J***V@795^&TJ4J\D98[(^[F*9G_EK&DDX%:0;/CWE6[+-7(I;N
M/?3-M<3#!G[PP/-K_]651YT?<;$!N]!R=@SX +\Q57$R<X '9I_Z10V&S\[,
MGHV*=9DBNE'UTZQKVM>.S76!G,7C3A)KB[W-S?%XW'W+,\-CW04$V*0".M/2
M.XW2-W'"[;9;*,QG" &($[!$C7'[74#@#D_&KB>Q.(?]$'#F:IR*>#3%?<)>
M3+FLXU(Z6I+8$<Z0'666R);O(G%R>YTXN4Z<_$J)D_=C/.O4S'5JYCHU<YV:
MN4[-7,74S.4*3P8*_6]<&K<^$$9S*2SW?&\CJOAWO0O=G2GH5N8H<P@?IFWJ
MGO#PO*\I>-3@=$.1JK%?2+&EQ@U= %><]6,5BG;KBA;Z%$4[ ]PT:ED_>E]*
M?TSA8'V*P3?%:@406BH(2*:[^JHETYEHMKDJ3&&+P4-+QD+DBR+7@!E!A]?X
M,NL\ST7TURR/A"69$H\/$G&U-PVWXVE1X %V?J7!4'A=28KGI"6"*)JQQO.C
MB+A2VBU<3_49EPYR12L4F8H=MX;EN BNW1(?T&;<+%P55%<2D*'<W-&( L,E
MS%);$?58*>(&SV-)E7J'VHAYP3ZCD,Y9=/LO$='HJ$6N[<*,[G^P,X;)3. R
MX';4L3MACX[DHZQQ ?%]E0)HU8@4<0UQ7TSN*\S\!JR:!,LG^[+V^32\DQE$
M]?_M];;F8KQE:]&1L&:"!V'G,,DLG_AT#G.[]9("H=?"P#R+3&U]R/.RM6?A
M8=1K4%U-N1_\;-WCX]/+P>E)N]7_[83U7[P^/3UA@XLO=Y;6%^<D'X!,_)B
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M1JX"&I$K*F$K'M.$BX@T!Y*Q$ #]>63Z*U4)[X]72*=%1-I(AHR\"_QOJ3@
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M?D]/GN_];1FKO*J3H3GA)K=[] (P6>)?D(9Q3:4A^/PF#,[2'EM[C;=.M'
M_+IQ6UF8!MF@JI *X6$(P38$HL%X.7A,"<E*^ZP2@>\T '<J#IWY1V['$O4
M(AO0&I7JDG $J2(;XXI-"NLU- F:DR2 W0<L 8,4X?A%-)A :SE 5DD#72 X
MMH4ND\I8#AB7G;?'CTBC87<5:9W(LF6SOJT6)4/)&-G8J9 ^5YA]P6J> H*
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M/^MS=R7^ 7\EZ&<,R;Z\H\"Y6[B7<T95\EKE?.Y5SMTGK7+>7Y=9S).;^#?
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M3^!@[-5L.9UOO@!VI/<(E)#OWR0Y/*!..+R3)&8#S95D 1MXBL0WD?I( ^'
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ME?/0N"P#'CU4.'BA4.*<:BN(7'899I7T@5"E3C-']N1-X-@\Y#DJHU#N2&4
M1M;D_(,<XW11I#29G6SZ^9Y&-7TB@VPY;9UJ*#F7%K%3E0T9QEF845$-AC::
MJ3U W$J?B7E'0L+4:1/MM8=V,)U%:;V?6MY-\S&*V,G@5JRM-@;XZ1A6%*\3
M]Q'0^QX!?\EI>.I=*]97R^B&]"2S$!FW"H125*V4QMP7>=?ZK%WFTJQXC+:)
M!'KTU#E!/CB4V*HJU3D"^J-WJ0W+456.897V0QN:3'5J2.NO(@VS@'/,[YBL
MGLPU.K@KU,-C-%"!3@QL):NE)BGBR)HW1#L2+)302'WK?5>Q<9EL1(E-5GA$
M5"Y9Q*4"I;$HB4TR(J5<)\#$0Y#3M#4YA:M)PM)1<CV&8[-[!C$"/#_#D (<
MT&1JF!>^9=(1U!RL06OP13-CPH?"&Y9JH13D_!D*CO5.!ILR0+M4? DO[-BT
MK\:NWEE3,5/Q<)7"8"?&F&ZS;V]D-@&')-?2LJ$W-B<+;F(6DZ^*%X!2/:9%
M2\Y+^HBR5(WQ_D_E-4A/*]$$0:*2@/V<>'ERZC1&O*3TC,;>4W))2._0!1RX
M9'&=Y.P?0MF!@ 98*"3Y@_)["#%-)OC4H0B2#+A !* "?1$!&2+H/($ QQ90
MF$M'07X;,DZ']0"'?W/8/DEC$M2T1DZ0_+Y=#G4O'ST;(H&O*@NW+" ;V8Q8
M,O("N=J41HEUDU:2QWB_H9IS#$/=PW]?4&9*P"(9$329## [-695%A'(3\4@
M1_-9_/4_'.=U_R-5:[3N_>%[7VRQ/5A;;!_ 8GNPMMBN+;8K3U__Q-B?:&KQ
M"1F3+" D3Y0JCB!._R17^9T5*:"OBEKBTQQ HX5?&=1W-*W]PJV3/%@V0;E:
M%X UI125VGA3=*4VS\W/[H,YV$KNC>";/R "K.[JI\9T,^9DV2>I>M)FNVHC
MH)?K?!#1E<"3 IUX<;8E>RJ=L[GG\1E1-9PZ1=WFK-2<OSJ$A.\2VC6D 9RP
M&SOD0_#$^OPB$.<L+2(^(YE;V_TJYT2<ZA'LXO$YTN_9_SS;??80._IDE_2_
M=UYL_R"1WI(!K6C!/CV18;\].KSLM<].VA<G/-8E_COJGO?.@;"=[MEQBW!;
MYLUZE12PF/YL,><NR4[U<S_=[-U3/SLK7K8?X17?=UQ^\'!5M+,^:6?;E 7/
M"MKW!]B]1@N(LT."^H^NX//L.4_F2.39U/F70 _8(SA5CX>K_T(WR='T]?*L
M>$TOOSR]]%!S7)YDCC]<G-\SJ4B+P2VUPXI^O_O;7HO 2U:EQ\H): /AHU&+
M6SO*S-XE-PKZJ\E:L0A_:L4]MY5'A1R37C\,=,$:*ZJ(G3RO'[5EX><V4-2:
MGW>,=+,"P;+&0JGEER_AU]0;._]*A@M9Z 3C#..A'N8.FO1N+UK7C&P)?KYP
M,+<0C%<_FMN(Z4N-YOYN]YKA@-RS+/VL^-K_L9VZ*SE@99?RX]_R^Y?PUEO]
M:PIDK=T;8Q66D#R6>&36&WJCW_K9X;\1O%P[CLB!EB?(!9U3BEVVQ;KNX7^6
M\V*_6'NQE_9BW_1$M8VU6_E1N97[")/VW=E R_B6=4##ROBR54RXV6@S]/EJ
M*^^U=N;%.ZYP%D=Z!X]6/8']>0&;=[XU1X>ZZJXN%GH'$YP3KO\T=N=I#WXN
M,OF3F<'*RSG\Z"S?%2FC=,FL;X9TMJ*%N7[21V\*+[C.[O;NGBLAO##P!C,D
MCL*DER115E/?7(;*S(#R06?CNGKHEP:4NB0LE5Y.$7(!I",.4@ZSFM+ &_1Y
M;:GUN>VZ3I<3VSFLB&*0FPVCR[K:;$<6-$^A(&6OYQ+'*NO@[MT#R<^XOW\N
M6M^YN<3)Y\/C\[/+[DGGHMWKGI]Q@/VG"DJ^ ?0O02)8E%@*/1^&5X)!][])
MB'4J2%F+'*^1YJB>C:[OK1.69GMN.4#?72L63D/PPS@0#L/*!M;=X  X?Z7K
M '43](G"7"]B+*$$7XA(%2O'PS!G@BK '2M\#^"E(&'4]?EO.)QE9^%3!:I(
M^H!2)F%4)OX.H:(4CII"NH"3RD'T40(-CZ<EE';3AEXK-6T*<X!W!\SS9M9L
M/*W48L"LA,A:-BKV#HPG8/R/4IR>*\/R@2LQ !<N0X2X,90]XSI7(J/(0R2$
MOPL<ZA"&1PE%,K#0\_T4L[\QZSN)L=2D2R77N80A_''E<5H9O\)EJ8#D<20#
M>!37F?('%.!-I:"XLQ%@46F%B;C9PMUG=P"3S#P*QJEH*DX%;$RLBR^95'5.
M3[T&"9]2/<)L@GE"T90@Z3!%%:'+J,\H2^S%]XQ; L?1+:5LRJ!*AC+!?=6[
M0?2FJ)<1]G =J60ZISLQOIR&X:N4CZ$9E,,ND99,Y.7L_51=T9F[";.J<%BX
M;8+N,:L]$67B&DG8!@"TBMG(?%;,+Z'2A)Q1H^I ^.9!K#7&]>YE(89RQ"BW
M@ZO%B>3D[:D6SN%L6Z+J!=UA%JY&*.!N=2E0!>9+RT'[ZG^-DVO8JZ$N-\&9
MY!)4.)&2QDA6:"PU4(:N*N%I[90!9[!>ZPR:+YY3KA;D,@FZY@S1N8)GU/%Y
MCF_#.$*"5H23 \,<A\68<N"]*WQEE&!:]A";3:Z1B<!GL#*)3.OTDXQ !&41
M4=<P&YAED5/M")F,10\.!#? 4 L$+8>@NC$.#S,$K3.>Y8G_5?YPDDDN3SXS
M#PL J(1^5^)0I?)V$@YR+.:7AE^AE/(T!91;%CI:L92RNXR4TNM^[)Z]=\[?
M.9_:?W[L0-?PZV7G"\@M9\<=%EMJA8*;Y YG2;'#P/K> *]818O(E-J@ .<E
MX*/(Y,U(197AJ2CB<4I6BJ<Q3AQD3A+IE!(4&9Y4@]<CPV=A)$-P![S+D*O
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M!1BEIT[)XA*I&CJ.@WZ2?&5-@_!U8F'W+L5JGY!M2&B4V($E&7K3?50'8N^
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MO@<G><LY_Q:)J9K.[O;VKLOFZNYX' ZE+_("5? QM7>,3".)3$L65JSLUA#
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M H<YGXJDC8#=6KDEYB_*?BX%$\$RAZFG3>A\RU+FCJ0M2K4-\TK0IDZF^E
MWX).LJ1(,8/J1.#%Q;Y6%7<GSZUTC]K>!Z)BMDK3I4NT2HY<EFYH.-8RSW+2
M:X%G]C46>QM[T;-#M1%R$JZC;H,C1,PQ"0J\3&.X!> 81G26J"8B%W[3\"UF
MU;!^M9>"5F%RO^#4!#*>Z3I)OU*W++/.9NE^)AYW\_C-M7O7YO655UO[KI+H
MY[$22Q3.1:T0JQ-/@/QLD&K7.1Z!@C=#?N<<:NB6*<5/HB1%BWHA"#BICRVU
M_J*6_H]*!^R'20L$?0M)R45#FN]APOE5\E50W4 J.0@S0*;R'0-"SJR*"UZ%
M'B6W*,*;8O@C*"=X[PR\;^4<0Q!*47YV-EYNPE B-'ZEDM$0]@<V.-9EA1;I
M!*72V=(+9ED)R03@:>258(ND70Z]R"0XBPT,;!S=8WPK9*4_'*N_7 7$@.G)
MP!+XE!<QGO'EO"JOUEZ5!_6J[*^]*FNORJKX_0_K0*IP\/[!EKG69<G9Q187
MBO2RDH+34@(UR"# <DG 0/8NX[FDZ(, #R0948G3NS?%W4I+O#^+X7UXY)\=
MOEA&ZSWIOGO7N>B<'7><[IGSKGW<NU3*K0P5UN)E6;,SE>](F=,('P?[NSJH
MTH2[<00E1\])ZYQQWL'=3'%KHE7_2KEQ*7MF2^%V_0@T[=Z2972_$^42"].\
M_*VUPZW_MC_WB$O-ONV\[YQU+MJGRNC@G)QW+IN-L_.>T_FCUSD[(5L%I0PY
MO0_M'OP#C/JB<]+MG5\X\']^#XT:G]H7O3_I?0=?_]^S\]_Q@<O/EY\ZQSUL
MI_-'][*')/"A>XE??>A< #5\@=]DP[WNQPY"4W3^Z!Q_[D&CS09^+,?&1A(:
M1?<=M7_F'/T)C7V4C;G.[^>?3T^<#^TO'>=CN]>YZ+9/3_]TVD!^Q[W.B=WO
M9:?7.Z4+SOF]V_M W9]TCDJS@C=H4BUI[EC-UN_KK:]@!CYY9M!M-M I/:TB
MB9#50):DEZ8'./083Z^,.;)@N'%(+["5#Y("K0P"<_])\F8C-XFWI.UAT%T0
MDL<*D3&4CH^=HQWI&FTX(0CJ*EF2&\#:VFZ)(\F"&](W48P7N^B-59A4<=20
MFPU]HV&%\W),&-UF:IB^4 9X&N4-8:8W;^(/QYZN+[P;YO-RF0NO@R@6QU)\
MG@'7J00[DT5-IMJ0P4ZDX_G!A65P*S1W8BH-.VM,S=AFP[B&=5(O*Z!X<)0/
M.. &A/AJX_ZQ/Y8]LV,13/$2-.$8EO]Z,3!;*"'>9"P*X720NT\%K= M3=Y]
MD7*L*$RX3T&I>=DALIR%S:V/&V\V%L2+8\OB"A1ZRMPC-TZM<R8D:"%"Y])0
M7#SA^CCWS+D6B,23J0PP6 OMX*)E)4^2C8IAHE(MVS4N]9H9/%9F\-LRS.#L
MW&F??.Q>7A*FS3OGM-L^ZIYV>W_>S!J6=U7S48JSG*#KI(F((>N &4B\)\S%
MG"09TR<:_P.=O<KW<Q2J+#&5HQ@DE&D*DG3(]B,=Z[X4*L#/1J%/;CZOEJ%0
M;>LAP1T$]<O/G3?P^]G62?<2).#V^])5Q@2*Y,<IOUDAK.!#M([SE1)X8T+W
M+$5*:-ZG:%(E'JKL(2L5(I&F4E%*HS6@0C%EF4MW>XHV+_00A!E2-9LX\4((
M4N\:39SL1TDF^592Y*[V6$CO(5T=<!?\502A+ZRP3#E/!"CU4@HZHXQ.44',
M&'M?X2,1!TF*-QNGZ (SIX,9IGX1$6Y:?5:%:]*(51HV2I#I5UDOGNW:'J:'
M]B,*Q;3.>J;'-HO7X7)TYE=1Z0!>]T4:*Y<QZ])C%?/)&>[7'B:",7I<.J:@
M3)TD.Q^P3_OVDM3.:&7D2PY4$Y."(^R^+U$"5P*W!4465!\2I ?,NO<()8+!
M#"+C("9RH#B^,/Z["%.)A<I4,J#9F-29ZY&(Z<M0ZA\<IT3!LEDU6XV=HR:^
M13NHK96CC-E2<OR\%([.^3%10C7.6.?1FC!C)N%RE#$B M2%&<_+RM61QS42
M'!$;3&0D4Y[H_O$L9R2%!V6H-)%:A;&>19:QUYI!.:(DXY?-VGI]3.0O8I!E
M,.6=U#"I[: KCN!/9200$+,5+2J;+$>36B&6":8#E:(EFPT^)JS3D9:'0J7J
M>V5Q,LM< 0]P42WVT>QLKYTT#^JD.5@[:7X-)\UCE@A_-AUL9WO).@WONB=P
M4KIM6_52V/XSX41!D2IOO07*8L74:< UWX(2I;R821H*#';C@)_4"P1BQZ0B
MQYM:WXHV,(9]6=K8F'7R%72 EQ["+"%V%$JC#*AD\#TQ>(S<9O;0[$Y NC7(
M7SK,QA@=9NPEF?2-4/";6U4!*+E7W_[")#G-ZU\FY>)E;02NK.A/$A%[TBB4
MXO6OK%1V4C1#. ]5+)*RA&' 1BYBBOC@4%XNZS"G56F$EB(UR T$YN(+]3YJ
M-F3R*L?2H?Z &O3BQD-$R@=!+R%=VPY;XQDHHM.*OBL-5C",']@0ABB@-&>]
MH)6T9ET# [=,;Y0=W96D##6%NY?$"/L:<5J9?EI: -B\AODTE'\NY2V4I]D$
MD;,)<FX8G )V8MM;2(8&WCK4:42<5U"A[@5R8<UE;YA/15&CP/?,6&5=#DJV
M3)@VY<RA!$;_90Q "TJ.3[SWC<,X$3<.=0B%#A<+;ASYM73+$3);F!',H S'
M56&U,D)W:BP*B&+GF&3'<HQ_*=#5 DH0LY#L&QF#('+6">A?6)B!V9TO6KP<
M^J"7EH75\0G?%*B:R74J4@:U9]U6YG1J'N,ZU7A(CFTK\2=T.:G(-<4!69&U
M$;'MK;DI.)>"E*]T=H0>*:KNW#XS3*R!<8UKY'(D(+,AN/$&=&E^M6<I\<?J
MKX8%:3*Q\@3X9%] 0!B1^@PFI15MY&/2AJEU;M@:B;&66J 4R7A<Q(@-Q)^7
M4W=OU*!MM#JY-?B;,4[IA-NP!"^>695+EF7P:Q;X&%C@SE(%P3Y=G/<XV."B
M^_Z#"72IF(]JZ%M;D0S>Z;24V^![L;3Y:[ V2@27SG,X$%6$2!U-8TNNE -J
M83J6TC$U.EQ]X:LXL5/"YOLH]1!TJ8O,V7>=5^PSV]EQ.0$B9]@I%*M2Z=4@
MNYFK3$TNXMK!,71FC8\(QY/$6Q0W1-(N3=0 1[)LP=Q)URO49M$\T6@Z-O>1
MCPTQ#D%"Z9D:7^2C+QO;$*>1: V_,IGUR &'7JIOCXH0CW4W,F)5$GU56K)<
MM@@/4:<,-<QH>,78:B:%F/G&-:Q]'HD^XH,J5"YC)#1%GY195,+* +V ?(<*
M"G"C:RRMPD"JUJ2W=-8F16.4.^)W8#!#K'0XT%65JHJ,#9UC-R[9IP3:T09T
M6).JBWG-]1X!UT,@@#HK\:12Y? $??J!TR-]]Y+TW<S YNV\<"D'R?);C@2F
M([%M-XK84^%C.![^CH[(2,SFJI.9F:]C6[,FY":%0ET6-+SR@ZK:S]@+%$JZ
ME-F4?E./G,54K"0"#B9D%Q#+!!9]*[!F&82H!5M7CS!+8&[2%\M91Q(/T>5.
M-8>A$EYE[%>*O?B8I ([I*0':V<T,C-Q>R-_6RO (AUG22-JAW%C:=G%);$I
MX <E.)KUF&%S%->%0B 65J(("K6RO'&9\**6\TYM<,73;="PKT<LJ66F/U1&
M!3FT+ !;<FWHRG8#]B5))$F4E"FD#*7.THK),(K*DHPJ%"3)6.?#52N<X)B+
MNA=#I72@_F^M#<F^I2;D%!$C0ZXTZ<L2JG*F8;.&#.&JQ(.Y<U!6!/MLHE:B
M#1,_)4=]S$.7Y9*KQY2E.9;L?.2)0M9:@ VE3/8PGRY0A*J9K;-HMPA9J[![
MT<K&TN*#98G?NZ-K9^WH>E!'UXNUH^O7<'3=.>-8;8;2O>'@/J(B?#O+50AM
M_]&ILU58 8DL(*%ZC394&1980O,:H-E6R+1Z+D*9Z8*?YM:JJ0]*,#>E\)L*
M%)4JL8>B<Z3B?S*J0#Y;6IK"Q$)&#S=N,1Z;K"ZMP2)DZAE^O,'A-%I"+X%/
MO^L>MQD&.^Q3\FZVB>\J9-M9& BI@*LD@TH)T'D+43*=U!3XR$<)@_TG&3==
M-E*Z'$_-OD<R;X83D!\1F2L+N)I"R;2CMQ;);QRC(8,@')217&XME908DX=)
MP?62.PQ7U*YKS)4)5:B2 4(;4LAI!N_SY*L(PK.K9]:*B[C_-"&FOR(+ZC8;
MM2RE&D1(I_*ULQ%N.MV\;"&<'PWMSN<I$LU>^VZLK AR5*(*K(J78P8B#,?E
MM$-T+8PGG#SDEO,#][=?M36JU"#DA(EAH4H_$+]1Y9J&A426RDW611E4YU(5
MGL!F:]%UR HX[H?0%ID!^3QHAEB!^\H2-1MX]_G,7$JS<&&E8:DI\40R3R[9
MHJI3<6+43/'TBNG6E"Q%)5P0!B ZGQ!<! TU.BV%;(4J AV>T!F7+1S-UNY&
M?W-C=]-12<0]="UC<=.+RO+"J&'8R.-UTV9YU;J0&:)< ?K?SG]:;R\_?SK<
M>?L<?\Q$GU8!VZ27L]9S*5D6Z-_I5-=NLG%=2N9F-!RC5P>O%0II%!)A4B&J
M90;8P4KCT>9X8,!ZAGAK21N:-%DIR#N96X=&Y#E;;GSK@4I4XR-@0<' (WKI
M%0&3?Q>36$HA%[C4!*:2)T.&ET K69!,<AG-B6HISV4N'MK\XXNW-#H.J:E$
MAND0%<BH:'LLUD*2WJLCPY.TY&N%<6RT-]7Z\"9:[H]2E?.E))=FX\9%?DZ'
M1\#1D#$KYO1XWYP<UEHOO R;F3,B8DX;1YLVPY* /"0YT5(3-- J]OR-/O&6
M<]<P8HHX3[W)R#+K^C@7P;5 C,=9^>6QMTIPAR$8@XRLB$83@(GX5?#&L787
MV6V1=ZN4QL*9+P.9WJ4#<=:RQ-.5)79N+BI."9B][D7);(":33T.A3OCRZB5
MRZW*W!)/"K$OK>CXOLBO$7V,E8XJJYR7\XRNPH%(9<S6@IH2<T T-.O5S*"6
M264%)F.(0.B$1 ;<Y-.8&&6 V;6>"Z=[Z=I"ZCZ3AF8\74M65N<U65Q9'40B
MQ  [.H25\;!6.MWK6'.,$U,XJYH\& 1^SNFAY/B@/&M=[<.SKO%<"DQA9E*[
M*58'3><A^5,75O(PR09&/7&MM7*=<I$YXM(P=YULD[F60AU*M&2TRJ/3DT-A
M*(V!YZ@JKIDT=!,O,G><"MVO+U2Y/;KW4@W0*P.29'3!5 .D:M8J2Y"HFH'E
M:HIZ*JZN=UF9DVOFY,Q,*<R6G9&%X?8+,^FG/\&=FTL2$YM^?_ZE<W&&X"&G
M[=]=Y]WYQ>>/!/)QV8$O2FFR/1VRQS7$9(@?BSMS0TUG=23YMDR>JP'5E>Y"
MTE LI!B*HS#5/6>,*%(F1: +&6,V,"!&2L::CPSY/)EO&[.SXMD:IB)EY7UE
MFW=8_//FE_S10"15Z)D;?"J[:Y_*@_I47JY]*FN?RH,CO'T$22#!ZL]H979M
M!@D,["PAAAAC]5$&XR_S4,4_*21!YY^6H5"6!\U'/'J"/L"JN, \7*D*2VQ:
M&S*$+@*8.E\'#$M<*T%^I]3Q."[@AP^16#65[2P%IHX(8"@[H,#PY?ST\UFO
M??&G4T%/)Z, XF8ON'Q+#B_6B@RTOO-)03#/X+;6 F3++M'H1"#4"C%C0%54
M0A_KRU  +Q:/+D5,AK','U* QQ2YB\)+Q#6KHZD*>1<*>?NO(AB2N(PA)G79
M;,LABI!R).LYV5E!^#9)171:3*MRA3BW@'"[$<4FEL )%%27CDN8W/+0U:%P
MVXC:"J>60W<9!2BG(/KY%14VO A#?H<C&>4,#_B@\EK9:62JQQF4@"D5@#GY
M^#9_RI/_8VGM+*;<]=!!V__W!7'K /5/Q>HG'/VL*[-'4[JJG7[DQ5];_V&H
MO*<Y71OL;SV#]0S6,_B^L+Z]M0KZH"KH;VL5]-=00>NXP@_A$=_ 1-K'QYU/
MO38"0Y^_,Y+[78-W+X;=?2CS:Y=QBX_;%YUWGQ&V^*+3/B'EAO_\?';2N;B$
MU3II-FR5IXL(QWB0$+FM?7K*2,J=BX^7N*@6?K(Y;HC!W/GC^$/[['T'K:[T
M%!Z*7O?\K'TJS:^X+=#D[Q^ZQQ] M&9LY7-X].+W+K1V=MYK-HXZ#OK:>J>=
MD]:=;]P\J.P%$OIJZ?5$5I^9)D5*:H]'Z7N,PE!.,70D6A5"%#<;]$*UT$S+
M06ST1#I'&.ANCHHCJS-1,YZ?8Z72F=:X&,K#GIVGW=MM8+V?K088WFK&W%?V
M_52]OV:[:G-%EP\BNA)X_[CH#LBV9$^EVVON+?>,[@JXR]2=86Z@FEMME:XC
M)&6XF/[OS']:5(2[[<9!\;[>H<^N;A"U@N4.!D.A8/G&F3O(4FMW.F82"AYJ
M:Y=8PD>QCW<_".!K7\*OF#_]KV18TH/6E/!K4<*"0:RW?[W]Z^U?;_]Z^]?;
M_S-M_W_OO-C^P96_I69U=P%\3W0>((>20:E]<<*#7^*_H^YY[_S\]-+IGAVW
M*C;\NZ/A&:)9L[#'/H@'9&&V'?U>.9?J^('ZW7NHCG?N>J4?]+BOV";U@W=%
MQ;S4)_/2=NOE@;$P_<!U O_;H:O@5V+?MQ!!'L4@'HO\<#1]O;S<8!5@_Q5%
MAC7-K68./:S)MSS9'7^X.']H<I-.^%NZABI.Z-W?]EH'BG.OP.^D)O 0+KT;
MXG[VUW$_#QKW\VH=]_-KQ/W\4,P$;'?K%0JA.SLO6GM4VWIG=Q]_JZ? 2\SL
M+2+AM%?E,5]ME #&]^S<58UN;'Q;+];!S:NU3&XUH[;<D%N]HEMB8;7Z[UN'
M/;7&*VR4UG5_B75]VSW<8'P;G6SNY0J/.P"%;Y/1>.YY3&HIUEVONUYW_?-T
M7>ITD:Q[\,8YIX2D[+5SBE4"U@+OL@+O34]4V[C''-W;$^KSH_.3/U&%?/ZA
M]_'T\/\#4$L#!!0    ( ,^)KU;Y6.JY: X  '4R   6    96@R,S S-3@Y
M,3%?97@Y.3 Q+FAT;>U;:V\;-Q;]+D#_@9O=& D@R8Z3M!O;-2H_DKAP;,.6
MN\VG!35#2:PI<C*<L:/^^CWWDB.-+"F16V\W!;9!8WE$7M[GN0].]M[W/ISN
M-QM[[X^[1_@IZ+^]WDGO]'A_;S/\Q+>;\>N]@_.CC^*J]_'T^(<G V>+'?%B
M*RM$3X^5%V?J3ERZL;2M\* EKE2N!T^P$5LOJGUCF0^UW1%;3_8W;-]GNWN;
M%_>6%.IST99&#[$LU\-1L2MJN_;>GI_UZERT!W*LS63GRWSL"E[K]6\JL U*
M!_O'O[P_.3CIB3=O.B_V-@\@-5'?7^1I#;:#1OK.I.+%]M?44A.)_FB[*^IB
M)\H6*G^R?U5(F\H\%0?:]9PS7G2SS&E;>/&3&@QR-1$'1B8WS8;TXG"DU4"\
MU5;:1$LCS@<#G:A<@,2?PVW76E?:!'1.;%HF:HSGXETNB=UKFX*5,^E3^4F<
M:E]H.Q27I5'B]7<O7S]+GC][]7P5EU_WLGD/.9G:Z&2)N]1=H%JWPNJ_X_CP
MI[/]>I62P!UIQQ?Y1-PJ/))VWI:BGT,WOMEXN24F2N9>N($83*T*:PJ781MK
MT"@)O?J1SH3ZC*=:0?\L]V,(LU*"FG[_+*7]K&]R.18_N:$HG.BKQ(V5N,H4
M*Z6;WFKO\F9CX')10*5>%]I901IQZ5].'U\#F0<2NSJ_[KT75]TS\?:R>W9X
M<G5XWA*'D&+0:8D/<B)>O&Z)[:WMEV)CG$H_VA6+N'-BDTY@ZED(XIUFX[1[
M\+PETES?*BOZ$R$#GF1EGCFOQ(9E8E&4D_UK"V^%JUJR(-&$'662*$/.K.#V
M2MX4H]R5PY$7VHI1";'$2$E3C$BU%4$98285Q4@)&0"1L*;90*3,QQ)@\4I9
M#:_X&5@H+G+E=4JP1&&T"C!!024%I *'J9QT(JT[;0P'W*)Z-G+_J72[,4Q5
M"WB<)&"28Y2.TO96^0)LY,I(<DTO!I"!/[7P,'-Y$10C/NAD))41Q\.1,^.6
MN!@=P4S+.#_^K)*2^8R<=T0M2HC=9B-78PE=RH*5A:#)I)T("A,9HX-U-!]'
MQ 8M/SP^IX_*^C*'IFU=,],@ZWR++K]A4C+(O\ U.%>?$UV0OSAQIPPC![E)
M)>:BMZM*L\U&#6$+)<>=L',$I4&!N2/7AR[@'CD@"33@@A019$SH%XH>DT>P
MQD<H9MK#W-T5(P1)W^@D&D1#*C+K2-/1!?1-*IZA_ S:X5A8-\L&OE!WX)S9
M8__LP\@Y[))0JO#+1"/00GPA)UN<)3*(HHCKP%AK(V?-"2]U&GVP(Z(Z3X0T
M'CJ4%&OD&,1K*L83; :G19E2R$0G;(F[D6-%]164)(E7F4[P!%OH_P2JA:L!
M$&ZH2O&PC;#R5@]E$6,;21*?A] 3NQLKDW$]PH0K*>;+' K)?<'9<JG0G2C4
MM^BI'_(IOH#UL8,<\"18R4Q65W0%ZD!GC!/'-G4(SJ'*)P = FE!J&/B]Q&7
MX%W)IU+'I BD/L Q^'25P*D*#:*$M]TLQT;* QTQXXH]G:SN57ZK",GPB1$U
M@EV]!LF=43YD8:\H-(*;0Q08,,7NJ;^W0"@Q9<H Z6M0]@"<AM-V#?RW4(EX
MC\Q#95.+,U4+[C96*44!'%4E(^N,&TXJ_.O0 ;?:E=Y,6F+> E\Z+,N,AA 7
MN2N4&^ND=EHV?=;N(Z!2D6HYM% SGE3'MD+T?N409#LECS[72(\D_#YQ0V45
MDUM"NFZQOAI2W@26)  _4-4V9$IH&_$.L,).0I)"''_LB/=*:,_Z&O<#"[3X
MP,D 9D<:[HC,Q67HH3)&6CGE#6%MAA*Y6SLH #5_,1.634>NK,EMB)V#SE6'
MF#DHO;;*(P7F;@S[X+AKBU4Y''3".LCU;\[*;SFS  K'!$/ W)!8?G6L9HC)
M, _/TZ3.>^F#E9).+%K6!-"5PU+Z-\:T>>!E2TYQMT=D>3M^]DMM0MA82FPJ
MH]WPH2JW%PB(:2X@W3+,#U%=%9RP=!JL[)TIN?Y@*$?  3V3$>4&"7"U 8'O
M7&[2CNCA>723(J>^+D7L($%1V5):LIH<46$$0GP0 EZ#FP0G0CB*8P/[AB17
M6N/@I1Y>K9!=B)M;:4K5 7Z14E-EJ.D/6H4(" "9%\3Q8C*3E,@@.15:I>**
M,J1N9#3+.6ZLO:<BY1$S /?+6]0-]&&D(2NKG0!@\AVD/!0:Z(0YH !,.46W
MGG7#A(S32&7%PVQCRNQ"C3/C)KSJ3J-"6)"V13+5R_4YZ"*#QVCCN+R+\6N=
M;?M"%B5B>(*,2KIW62A!<3R*]80J@&;CU=96:VMK*QC&5SAP&+QJFDB(7; 1
MZ#R+_GG.]$27SHR*?LY.(^K?!!Y'DAB$PMN<KJ&B$!3LS2I/-/&"3 2-H.@)
MW CUJ80>8[F6&.>YO.)%D<_D2WS"3?"47,H%*(QSB'?&]4'W"BT(7/6#S&]4
M45-RLQ&2X579_Y46X'P$XHJ!%8RLR)/@2&'6]$!DH6TK_>F/(]@BC^N=/#WS
M;^TV$I8RZ8ZXD$.%'A%&(<?%^:+=CN/#O:.3G^=G9NW"93OBN]F)[;XK"C>.
MS_JHF54^?1:<>3O[3/"D4YS?ZQZ<'J,3.3V]Z!X=G9R]^^')UA/^_>JB>UC]
M'H^,U"""D9D':]6G73A?6HQ(5UM/E\T">Y<5#>0A+I^K-A_\S_?]1@UXQU&U
M(Y)^^?+IS%*]HV4K7CU=,4)8L?[EO?4\#IT_9+-W27^1EO 3ZE]B"6ZMVWT%
M]('$&9MO#>N K\4!:'UL=C%_8LU%-LE'@EO\P8Q+K"TZ[X,CY;\?HU462A>0
MO-YYQ\ZE&EV@.)9]HP1-!PC34N0,'+S]^FD%;!&._0R#BBFN-ALU8"42%;Z%
M?DC:4%7)?%)1J\ZIL@XS28>&<HV6A(D!+?I^/2X"NC<;,RY0";&4* ,"<@.*
M"_I-6Z0B8^A43Q3@EX."YA8GR%AIROU)2\BULJ=8GCR)CWF=+^1-087-JGP)
M,0LD%DH6(7E0?>-#B9)2Y_6/*E%6V>_RZGH^]0GN %#>V=^9K^[QBSJ0O7H^
M#XFU'(Z2V((92QK&FPD/G/!T*L!C.-)*/PJ%_OH<+#C1G/.@N\PYFI0*WE7W
MI]@##TIC)DPL]*VD4^CS>U2:"[4)<7V/"]2>]_R=BA6_RH*@O%V_^#A&QXW"
M&)T2]=CPL@M#?F;3>[&/1BQP@,I9U2*#510B(Z')$O?:;-XOWZ)P[RM_=7EL
MIN@T KY,,?JA>ZP:.NKHB4"P=;-Q7Z(E/2#8IIE7.@O#Z>I:G+) _AMLWU;"
M]ZZ(O_U]JTM_^':PVW=EL6(63K>%?P9CCRK^ERN]^DW9?6TL*"$.FZK+ !'N
M K+I6$7<6'=G"<K?FE*G>CA&*Y&C7PS-+O62CW1QT&Q\]>8@WEPL6I*'6V@\
M "Q]H_T(CDTM[0"UIR/'5]Y3\$K3 C*'S2@:4VZIVS2/R>,\LAHQ:1I_<0<^
M4B:CN4@<0\TUV"G0R[@LC*AH%"(&TA?AJA:P4W!*Y!Z2Q@<D][19G[;PK;FR
M(C[U=+^@(ZKP^"5#-\X5!M"3BL>@']9,F$6@WZ(!<,DIBC(=2"%3J8+ ?BP]
M\LP$!:&B^TK:,-9)[@9LT\3/"4X#7YV,@N33@6VSX6=31IR6 #YR&GAKR_T]
M"3N=$B#>:#KO.TNB[L[E-SX 8*45F<A4@:&6&!)52^#3JN9EJN0ROD5&F(T
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M>'L4;\]H]CH+.#3?(U>BYQD[)#P(O^J5HF:C0@-6#T[VCG5-O8.L8H93?#5
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MNA<'#83'$BKYK,I0+%.*S6&=N?CK4JT/LDO0K7!HV .Z8#-X60LTS4Q-+?\
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M#02DDOME9,DQS1(Y@/5"TI8Z/]T S+9./0Q=4)P YN!3DDKOEY3%(TE3>3\
MT_X!Q29V30MLV.2EK0R*&- >R$P1@<J0<+"Y?)&K<[%,&MC8FMXG/"W;7?Q4
MXF 1,AT.I*@(0S+.$TFUVQ ]#+64KND!K)K<&+*@B+%[ UE1<E3H_4-R2>-!
MB%0Z/X 8-NUXE*( X6@ZZT-#J'V"<95D$4Z5ERNQ+>MHGD7K&A#0K@E)2Q@4
M*) [$!85H)DI0KP"\R^"^3!<:DH_L+2LVE&I9 &"8GKKPT3JO4 RVW+>< W/
M.+#4V4W9'K/5_5E %P0H/>9:=VV5O &*IQGHDN9)OI?/T]UL-RO"+8UK2URQ
M 9G33)CE0;  F#(94#(D=4@)O?2\ODM <_D0(]@<4^:6 +O))@5-34 D6(T!
M-!RTQ3.E7HB8B9&)XW1.8[+[F>S!=K5T;ID ;#:A,$0!46%W!F!1BE&A1D+N
M!8P[GFPPWR^2J&>J: O=H@$9;;)AJ@*" [ &T%&JT6(^\SF3+/%N'@M0DX=$
M/0_>0PFH=PM+C^TF,X X('2Z'0($B2#4C/()TIQ&C#^SVN,.,[85 ^!^QF)X
MA=(3Y1:J04UHHM49$A!@0WP"F#5"/ZAG4A"3[_$4%2!9@Q?B+N)8'*BL_.<Z
MH>08;+]5ZY:N#KM-IBS"@$B"W0'\E,H/^@.2,>B6A@+-] U-G?J'9CH4FFG0
MT$S? \WRE04"S<D;FGKB'YJ3H="<! W-R;N@$1WO=:R9B8^W?,E>;0]G@THO
MR+2M6H$YR,+#I>6M#Q89(-<S,L0G)L7"ZI;?<?:2T A>,D-R+\  IJW4&-KP
MT+$;[..G6A#K.*]CC5J4]WY)M,S/*-,T:1]BE"8\2)K&>@<7I?:)Q!W+<IS^
M.WGN/!&WB[W@835LA:2A# \5F[T^8%0,$D$^3JQ+7.4-#>NK9$:YNU> +;8.
MKP#7"H. P.:H_0JPNGJB1*Z[63+*"09&A&:QLTZVF*KZN%861A>W#;5ZN/A>
M"XV/+[+,[I+>/3(*/R#0EKCJ:<B<[FVS/(@>!TR9O5[(4*'S=#5>9IC([,-W
MK<S9S&[:J29R71!$[YIN6M.T+G?<F[_R)!=[GK'-9DO+NSRVYP8!G:M>[K2I
M>]PJ"J+WNYR9))1:U!0[QF+!TB1*\H2N?Q$GGSS!ME;91*Z @ UJ&MJ*(%
M;9D<'(1(*QU#<,>)A)"(CBA> I2)A?CMPX-UMN\2NX*BW["& U8& 4FO/1,6
M$3".:A%(A: BQB\V\RS;$OXF>"PAGA "S0,@M?0AX@29[(5*!?ID:T&BK9@?
M]\?3U3+)4]O)95OB;$X"S%4SDE$>!!N *9.%H@RQ!W0\_<OJKTA'.>[^&[;D
M6":/7>PW*Y8"V:>L*E<0=%C4'%@D0:  ^S)IN&&HE"*E]9&=JF'6TARCW!4
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ME56@WV0EJ*C%]OOE]4W7XI/8K#>)OU8X(V++?P%02P,$%     @ SXFO5H$
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M'OFZM1O<*VF+;]PO]]I5N^5_4$L! A0#%     @ SXFO5O)_YF%V'   BI(
M !(              ( !     &5H,C,P,S4X.3$Q7SAK+FAT;5!+ 0(4 Q0
M   ( ,^)KU;BNSOPUA$  $5S   6              "  :8<  !E:#(S,#,U
M.#DQ,5]E>#$P,#$N:'1M4$L! A0#%     @ SXFO5NN0&'9-$0  0FP  !8
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M,#(S,#4Q,"YX<V102P$"% ,4    " #/B:]6@/EG^OX*  " A@  %
M        @ 'TD@  ;&%B+3(P,C,P-3$P7VQA8BYX;6Q02P$"% ,4    " #/
MB:]6@0 6#%('  #(5P  %               @ $DG@  ;&%B+3(P,C,P-3$P
>7W!R92YX;6Q02P4&      @ "  2 @  J*4

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
